Hyperbranched dextrins for topical use in the prevention or treatment of at least one symptom of skin inflammation.

Abstract

The present invention relates to hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins for their topical use for the prevention or treatment of at least one symptom chosen from redness, heat, swelling and pain, as well as for the prevention or treatment of symptoms of skin inflammation and inflammation of the mucous membranes. It also relates to the use of these hyperbranched dextrins, and preferably hyperbranched and hydrogenated dextrins, for preventing or reducing or eliminating the irritant effect induced by ingredients contained in cosmetic or dermatological compositions.

Description

Title of the invention: Hyperbranched dextrins for their topical use for the prevention or treatment of at least one symptom of skin inflammation. Technical field

[0001] The present invention relates to hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins for their topical use for the prevention or treatment of at least one symptom chosen from redness, heat, swelling and pain, as well as for the prevention or treatment of symptoms of skin inflammation and inflammation of the mucous membranes. It also relates to the use of these hyperbranched dextrins, and preferably hyperbranched and hydrogenated dextrins, for preventing or reducing or eliminating the irritant effect induced by ingredients contained in cosmetic or dermatological or other compositions. State of the art

[0002] The skin constitutes both a living anatomical barrier and an exchange zone between the body and its environment, the effectiveness of which determines the maintenance of a good homeostatic balance. It comprises a superficial layer made up of the epidermis, and deeper layers forming the dermis and the hypodermis. Each of these layers has specific properties allowing the whole to react and adapt to the conditions of its environment.

[0003] The mucous membranes that are the subject of the present application are the membranes that line the internal cavities of the body, chosen from the mouth and the genital organs. This coating is a stack of cells called epithelium. In this epithelium are specific cells that produce mucus, hence their name. This mucus will serve to lubricate and protect the organ that is lined with it. The mucous membranes therefore play a protective role and are connected to the skin. We can thus sometimes observe inflammation of the mucous membrane, a fold of the mucous membrane, or lesions of the mucous membranes.

[0004] As a protective barrier of the body, the skin and mucous membranes are subject to numerous attacks which can lead to discomfort reactions or even, in the case of very intense or more serious reactions, to phenomena of skin or mucous membrane inflammation.

[0005] Skin inflammation may in particular be induced by skin irritation which occurs upon contact of the skin with irritant agents, such as chemical substances like cleansers, or such as mechanical actions like shaving, exfoliation, peeling, hair removal. Skin irritation can also be caused by temperature, climate, ultraviolet radiation, or even air pollution.

[0006] Irritation of the mucous membranes, for example the oral mucosa, can also be induced by certain foods or drinks leading, for example, to the formation of mouth ulcers, or by friction, for example from brushing with a toothbrush. The genital mucosa can also be irritated locally, following repeated friction, overly aggressive soap, an excess of ovules, very close intercourse on a slightly dry mucosa or an unbalanced flora.

[0007] These irritants cause irritation of the skin or mucous membranes, which activates the innate immune response, the first step of which is inflammation of the irritated tissues or mucous membranes. Skin or mucous membrane inflammation can also be caused by pathologies involving an inflammatory process.

[0008] The action of an irritating chemical substance depends on its ability to penetrate the upper layer of the skin, the stratum corneum, which acts as a protective barrier. Regarding mucous membranes, the penetration of an irritating chemical substance is much easier because the mucous membranes do not have a physical barrier made of keratin cells, but are simply made of non-keratinized epithelial cells into which the substance can easily penetrate. Once the skin barrier has been passed, or once it has penetrated the mucous membrane, the irritating substance then comes into contact with the living cells and interacts with the endogenous substances naturally present in the latter, thus causing disturbances in the biological functioning of the skin or mucous membrane cells, or even tissue damage. The first biological response is an acute inflammatory reaction of the cells of the damaged tissue.This reflects a defense of the cells against the invasive product in order to accelerate its elimination according to the innate immune response.

[0009] Irritant substances indeed cause reversible skin damage. By applying them directly to the surface of the epidermis, their irritant potential can be assessed through various parameters such as the expression levels of the main biomarkers playing a role in skin inflammation.

[0010] The inflammatory phenomenon is composed of four symptoms: pain, heat, redness and swelling of the tissue. Its intensity is proportional to the degree of irritation (dose-dependent response) as well as to the quantity of cytokines produced by the keratinocytes of the epidermis in order to induce and control the early inflammatory response. The cytokines having a major role in the inflammatory cell response are interleukins IL-1a, IL-6 and IL-8 and tumor necrosis factor a (TNF- a). IL-1 [3, IL-8, RANTES and VEGF are also biomarkers of inflammation.

[0011] There is a continuing need for new agents, of natural or plant origin, capable of effectively preventing or treating a symptom chosen from redness, heat, pain and swelling as well as of effectively preventing or treating skin or mucous membrane inflammation.

[0012] Furthermore, compounds known to be skin irritants such as oxidizing products used for example for hair coloring, abrasive products such as synthetic microplastics, mineral powders or pigments in cosmetic creams, surfactants and solvents used in washing or cleaning compositions, acids such as for example salicylic acid used in peels, compositions for exfoliating the skin or promoting cell renewal, or even retinoids used in anti-aging compositions, are generally used at low doses. However, the use of even small quantities of these compounds can cause irritation in the case of sensitive skin.

[0013] It is thus also necessary to identify compounds which make it possible to prevent or reduce or eliminate the irritant effect of ingredients, in particular ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary or domestic use.

[0014] FR3093429 describes the use of branched dextrins in oral care or hygiene. dental.

[0015] FR2884422 describes an anti-inflammatory composition for the intestine comprising branched maltodextrins.

[0016] EP 1 169 015 describes a cosmetic composition for the skin containing dextran and a weak carboxylic acid.

[0017] US2019192539 describes compositions for the prevention or treatment of inflammatory skin pathologies or severe pruritus including ursodeoxycholic acid solubilized in aqueous medium.

[0018] EP1006128 describes branched maltodextrins and their preparation process. Summary

[0019] The applicant has demonstrated, using a two-dimensional reconstructed human epidermis model, that the hydrogenated hyperbranched dextrins according to the invention induce a reduction in 4 biomarkers involved in inflammation (IL-1a, IL-1 [3, RANTES and VEGF).

[0020] The dosage of the inflammation markers IL-1a and IL-8 (following inflammation by sodium lauryl sulfate (SLS) in aqueous solution at 0.5% by weight for 6 hours made it possible to show an action profile of hydrogenated hyperbranched dextrins similar to the action of Betamethasone at 0.05%, a positive reference control for the anti-inflammatory effect.

[0021] Following these results, additional research was carried out and revealed additional inflammation biomarkers, also impacted by the treatments carried out.

[0022] In this subsequent study, the IL-1α assay confirmed the previously obtained results. Indeed, the overexpression of IL-1α during treatment with SLS was compensated by treatment with hydrogenated hyperbranched dextrins and allowed to fall below the threshold value of interleukin overexpression. A decrease in the expression of RANTES and VEGF was also observed by treatment with hydrogenated hyperbranched dextrins after SLS inflammation. In addition, it was also shown that IL-1α is underexpressed in the presence of treatment with hydrogenated hyperbranched dextrins.

[0023] Thus, it was found that, for these 4 biomarkers involved in the mechanism of inflammation, treatment with hydrogenated hyperbranched dextrins induced a reduction in these signals.

[0024] The applicant has also demonstrated that hyperbranched dextrins according to the invention make it possible to maintain the integrity of the membranes of the cells of the reconstructed human epidermis, and this in a manner as effective as betamethasone.

[0025] It has also been demonstrated by the applicant that the application of an aftershave lotion comprising hyperbranched and hydrogenated dextrins according to the invention made it possible to reduce intracellular water loss compared to the placebo lotion.

[0026] Finally, the applicant has shown that the dextrins according to the invention significantly reduce the redness caused by SLS from 10 minutes compared to the placebo group and the reference group, this reduction then being maintained for up to 7 days. It has also been demonstrated that the dextrins according to the invention make it possible to significantly reduce transepidermal water loss from 30 minutes after application, then in a progressively increased manner over the treatment period ranging from 2 to 7 days, to reach a value of reduction in water loss compared to the placebo group greater than approximately 6.6 units (i.e. a difference of approximately 195%). The dextrins according to the invention therefore make it possible to maintain the hydration of the skin by maintaining the barrier function of the skin.

[0027] Thus, the present invention relates to hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins for their topical use for the prevention or treatment of at least one symptom chosen from redness, heat, swelling and pain.

[0028] The present invention also relates to the use of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, to prevent or reduce or eliminate the irritant effect of ingredients contained in compositions topicals for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary, domestic use (for example detergents). Detailed Description

[0029] Hyperbranched dextrin

[0030] According to a first embodiment, the dextrins useful for the therapeutic use which is the subject of the present application are hyperbranched dextrins.

[0031] By "dextrin", the applicant means glucose polymers obtained from granular starch by pyroconversion, usually by the action of an acid in a generally dry medium, that is to say on granules in the form of dry solid particles, containing residual moisture imposed by the conditions of physical equilibrium at a given temperature and pressure. Thus, maltodextrins and pyrogenic dextrins fall within the general family of dextrins useful in the invention when they have been modified to be hyperbranched.

[0032] In the context of the invention, by "dextrin", the applicant also means glucose polymers resulting from the liquefaction or hydrolysis of starch by acid or enzymatic means and generally called "maltodextrin", "starch hydrolysate" or "glucose syrup", provided that these polymers have been additionally modified by chemical or enzymatic means, in particular by branching enzymes, to have glucosidic bonds between the anhydroglucose molecules, significantly different in terms of nature from those of the starch from which they are derived. Thus, maltodextrins, starch hydrolysates, glucose syrups and pyrogenic dextrins fall within the general family of dextrins useful in the invention provided that they differ in terms of carbohydrate bonds from the starch from which they are derived, including "atypical" bonds.

[0033] By "hyperbranched dextrin", the applicant means a "dextrin" having glucosidic bonds between the anhydroglucose molecules, significantly different in terms of nature and quantity, from those naturally constituting the starch from which it is derived. It comprises glucosidic bonds between anhydroglucose molecules naturally present, the 1-6 bonds, but in greater quantity, and glucosidic bonds not naturally present in starch, called "atypical", the 1-3 and 1-2 bonds. Thus a hyperbranched dextrin is a dextrin comprising a large proportion of branching glucosidic bonds compared to the total number of glucosidic bonds present in said dextrin. The term "hyperbranched" can also be replaced by the term "highly branched".

[0034] By “large proportion” is meant a proportion of branching glucosidic bonds greater than or equal to 5% relative to the sum of the branching glucosidic bonds and linear glucosidic bonds, preferably greater than or equal to 10%, more preferably greater than or equal to 20%, more preferably greater than or equal to 30%, more preferably greater than or equal to 40%, more preferably greater than or equal to 50%. Branching glucosidic bonds are bonds generating non-linear chains, in proportions greater than the normal values ​​of a native starch. The glucosidic bonds generating non-linear chains are the 1-6, 1-3, and 1-2 glucosidic bonds, as illustrated in [Fig.l] [Fig.l]. The 1-3 and 1-2 bonds are the atypical glucosidic bonds. Normal values ​​for these bonds in a native starch are about 5% for 1-6 bonds, and about 0% for 1-2 and 1-3 bonds. The remainder is composed of 1-4 glycosidic bonds, or about 95%.The 1-4 bond is a bond that creates a linear bond.

[0035] For the 1-6 glucosidic bonds, characteristic values ​​of the hyperbranched dextrins useful in the invention are values ​​greater than 5% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, preferably greater than or equal to 10%, relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds and more preferably greater than or equal to 12% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, and most preferably greater than or equal to 15% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0036] Thus, according to one embodiment, the hyperbranched dextrins comprise at least 5%, preferably at least 10%, preferably at least 12%, preferably at least 15% of 1-6 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0037] For the 1-2 and 1-3 glucosidic bonds, the values ​​useful for the invention are values ​​greater than 1% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, preferably greater than or equal to 5% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, and more preferably greater than or equal to 10% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0038] Thus, according to one embodiment, the hyperbranched dextrins comprise at least 1%, preferably at least 5%, preferably at least 10%, and preferably at least 20% of 1-2 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0039] According to one embodiment, the hyperbranched dextrins comprise at least 1%, preferably at least 5%, preferably at least 10% and preferably at least 20% of 1-3 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0040] For the 1-4 glucosidic bonds, the values ​​useful for the invention are values ​​less than 70%, preferably less than 60%, preferably less than 50%, relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds and preferably between 42 and 50%, relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0041] Thus, according to one embodiment, the branched dextrins comprise at most 70%, preferably at most 50% of 1-4 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0042] Preferably, the hyperbranched dextrins, preferably hyperbranched and hydrogenated, useful in the invention have a content of 1-6 glucosidic bonds of between 5% and 40%, preferably between 10% and 30%, more preferably between 12% and 22%, and most preferably between 15 and 20% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds.

[0043] According to one embodiment, the hyperbranched dextrins, preferably hyperbranched and hydrogenated, useful in the invention have: - from 5% to 40%, preferably between 10% and 30%, more preferably between 12% and 22%, and most preferably between 15 and 20% of 1-6 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 50% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-3 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-2 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds.

[0044] Apart from the use of a well-known pyroconversion process applied to granular starch to prepare dextrins, i.e. by using an acid on a granular starch, typically at high temperature in a dry environment, these branching bond contents of a starch can also be obtained by the action of a so-called "branching" or "rebranching" enzyme on a liquefied starch, such as a maltodextrin, a starch hydrolysate or a glucose syrup, possibly previously or subsequently hydrogenated.

[0045] These branching bond contents can therefore be obtained both by the action of a so-called “branching” or “rebranching” enzyme on a liquefied starch and / or by the action of an acid, typically at high temperature in a dry medium, on a granular or liquefied starch.

[0046] According to one embodiment, said hyperbranched dextrins have a number-average molecular mass Mn less than or equal to 10,000 g / mol, preferably less than or equal to 4,500 g / mol, more preferably between 1000 and 3500 g / mole, more preferably still between 1500 and 3500 g / mole, and most preferably between 1800 and 3200 g / mole.

[0047] According to one embodiment, said hyperbranched dextrins have a polymolecularity index, ratio of the weight-average molar mass to the number-average molar mass, noted IP, less than or equal to 15, preferably less than or equal to 10, more preferably less than or equal to 5, and most preferably less than or equal to 3.

[0048] According to one embodiment, said hyperbranched dextrins have a reducing sugar content of less than or equal to 20%, preferably less than or equal to 15%, more preferably less than or equal to 10%, even more preferably less than or equal to 6%, and most preferably less than or equal to 3% relative to the total mass of the hyperbranched dextrin.

[0049] According to one embodiment, the hyperbranched dextrins useful in the invention have a relatively high residual 1-4 glucosidic bond content. This 1-4 glucosidic bond content is between 42 and 50% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, in combination with a 1-6 glucosidic bond content of between 12 and 22% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds. Preferably, the hyperbranched dextrins useful in the invention have a 1-4 / 1-6 glucosidic bond ratio of between 1.9 and 4.2 and in particular of between 2.3 and 3.5.

[0050] According to one embodiment, the hyperbranched dextrins useful in the invention have a content of 1-3 glucosidic bonds of between 1 and 10% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, in combination with a content of 1-4 glucosidic bonds of between 42 and 50% relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds. Preferably, the hyperbranched dextrins useful in the invention have a ratio of 1-4 / 1-3 glucosidic bonds of between 0.02 to 0.24 and in particular of between 0.1 and 0.2. According to one embodiment, the hyperbranched dextrins useful in the invention have a content of 1-2 glucosidic bonds of between 1 and 10%, in combination with a content of 1-4 glucosidic bonds of between 42 and 50%.Preferably, the hyperbranched dextrins useful in the invention have a ratio of 1-4 / 1-2 glucosidic bonds of between 0.02 and 0.24 and in particular of between 0.1 and 0.2.

[0051] According to one embodiment, the hyperbranched dextrins useful in the invention have: - from 5% to 40% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 20% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 15, - and a number-average molecular mass Mn less than or equal to 4500 g / mole.

[0052] According to one embodiment, the hyperbranched dextrins useful in the invention have: - from 10% to 30% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 70% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 10% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 10, - and a number-average molecular mass Mn between 1000 and 3500 g / mole.

[0053] According to one embodiment, the hyperbranched dextrins useful in the invention have: - from 12% to 22% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 50% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-3 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-2 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 6% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 5, - and a number-average molecular mass Mn between 1500 and 3000 g / mole.

[0054] Hyperbranched dextrins useful for the invention are commercially available, such as the products “Nutriose® FM 06”, “Nutriose® FM 10” and “Nutriose® FM15S from Roquette®, or the range of products “Promitor® Soluble fiber” from Tate & Lyle.

[0055] Other commercial products available under the names "STA-LITE® Polydextrose" from Tate & Lyle, or "Oliggo-fiber®" from Cargill, are hyperbranched polysaccharides or oligosaccharides which, as is or after possible hydrogenation, could likely exhibit a soothing property like the hyperbranched dextrins according to the subject matter of the present application.

[0056] Hyperbranched and hydrogenated dextrins

[0057] According to a second embodiment, the dextrins useful for the non-therapeutic use which is the subject of the present application are hyperbranched and hydrogenated dextrins. Such dextrins can be obtained by subjecting the hyperbranched dextrins according to the subject of the present application to hydrogenation, or by applying a “branching” or “rebranching” process to a previously hydrogenated dextrin. The hydrogenation can for example be carried out by subjecting an aqueous solution of hyperbranched dextrin to gaseous hydrogen in the presence of a catalyst such as Raney nickel.

[0058] To the embodiments previously presented for the hyperbranched dextrins, an additional characteristic can thus advantageously be added, namely, a reducing sugar content less than or equal to 5% by weight, preferably less than or equal to 3% by weight, more preferably less than or equal to 2% by weight, more preferably less than or equal to 1% by weight, more preferably less than or equal to 0.5% by weight, and most preferably less than or equal to 0.15% by weight.

[0059] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the invention have: - from 5% to 40% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 4% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 15, - and a number-average molecular mass Mn less than or equal to 4500 g / mol.

[0060] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the invention have: - from 10% to 30% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 70% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 3% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 10, - and a number-average molecular mass Mn between 1000 and 3500 g / mole.

[0061] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the invention have: - from 12% to 22% of 1-6 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 42 to 50% of 1-4 glucosidic bonds compared to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-3 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-2 glucosidic bonds relative to the sum of 1-2, 1-3, 1-4 and 1-6 bonds, - a reducing sugar content less than or equal to 2% relative to the total mass of the hyperbranched dextrin, - a polymolecularity index less than or equal to 5, - and a number-average molecular mass Mn between 1500 and 3000 g / mole.

[0062] Hyperbranched and hydrogenated dextrins useful for the invention are commercially available, such as “Nutriose® HM 06” from the company Roquette.

[0063] Biomarkers involved in inflammation (IL-1a, IL-1[3, _ RANTES and VEGF)

[0064] Inflammation is essentially an innate immune response of self-defense against harmful stimuli, including infectious agents and physical or chemical challenges. It is an orchestrated and adapted temporary modification of cellular functions in order to return, if possible, to the previous state before the aggression. The temporal expression profile of cytokines in epidermal keratinocytes is important in the orchestration of inflammatory responses (Kataru et al., 2009). IL-1, 6, 8, and TNF-a are known to be potent inducers of keratinocyte-derived VEGF (Detmar et al., 1995).

[0065] IL-1 is a key pro-inflammatory cytokine that mediates the acute phase of inflammation by inducing local and systemic responses. IL-1a functions as an "alarm." Upon necrotic cell death, IL-1a is released into the extracellular space where it stimulates chemokine production, leading to the infiltration of neutrophils and then monocytes. IL-1a is constitutively present in the various epithelial cell types of healthy subjects, whereas IL-1a [> is primarily induced under pathological conditions.

[0066] The mediators RANTES and VEGF, for their part, are growth factors for connective tissue and vessels.

[0067] RANTES has been shown to induce endothelial cell spreading and migration and participate in the formation of vascular networks through secretion of VEGF. VEGF is a key mediator of cutaneous angiogenesis and vascular permeability, which is involved in physiological processes such as wound repair and hair growth, as well as in pathological conditions including skin inflammation, skin cancer and psoriasis. In many skin conditions such as psoriasis, contact dermatitis, wound healing and skin neoplasia, which are closely associated with angiogenesis or chronic inflammation, significant induction of VEGF is observed in epidermal keratinocytes, suggesting that increased VEGF plays a key role in these skin problems.

[0068] The chemokine RANTES is a chemoattractant for eosinophils, memory T lymphocytes and monocytes. This chemokine plays an important role in chronic inflammatory and allergic diseases.

[0069] Advantageously, it has been found that, for these 4 biomarkers involved in the mechanism of inflammation, IL-1a, IL-1 [>, RANTES AND VEGF, treatment with hyperbranched dextrins induces a reduction in these signals.

[0070] These results allow us to conclude that hyperbranched dextrins, preferably hyperbranched and hydrogenated, are effective for the prevention or treatment of at least one symptom chosen from redness, heat, swelling, pain, as well as for the prevention or treatment of skin inflammation and inflammation of the mucous membranes.

[0071] Redness, warmth, swelling, pain

[0072] The present invention relates to hyperbranched dextrins, preferably hyperbranched and hydrogenated, for their use in the prevention or treatment of at least one symptom, chosen from redness, heat, swelling and pain.

[0073] Prevention of at least one symptom chosen from redness, heat, swelling and pain means prevention of the appearance of at least one of these symptoms, but also delay of the appearance of at least one of these symptoms, as well as prevention of the worsening of at least one of these symptoms.

[0074] The treatment of at least one symptom chosen from redness, heat, swelling and pain means the disappearance of at least one of the symptoms, or at least the reduction in the intensity of at least one of the symptoms, for example the reduction in the intensity of the redness and / or heat and / or swelling and / or pain.

[0075] Epithelial tissues

[0076] According to one embodiment, the at least one symptom is located at the level of at least one epithelial tissue chosen from: keratinized multistratified squamous epithelium, non-keratinized multistratified squamous epithelium, stratified columnar epithelium, ciliated or non-ciliated pseudostratified columnar epithelium.

[0077] The epidermis is a keratinized multi-stratified squamous epithelium.

[0078] The oral cavity, the vaginal mucosa, the urogenital mucosa are non-keratinized multi-stratified squamous epithelia.

[0079] The nostrils and conjunctival cul-de-sacs are stratified columnar epithelia.

[0080] The nasal mucosa is a pseudostratified columnar epithelium, ciliated or non-ciliated.

[0081] Thus, according to one embodiment, the at least one symptom is located at the level of the epidermis or the oral cavity or the vaginal mucosa or the nostrils or the conjunctival sacs or the nasal mucosa.

[0082] According to one embodiment, the at least one symptom is located on the epidermis, preferably the epidermis of the skin or the scalp.

[0083] According to one embodiment, the epidermis of the skin or scalp is a sensitive epidermis.

[0084] Skin inflammation

[0085] Skin inflammation is understood to mean the presence on the epidermis of four symptoms, namely redness, heat, swelling and pain.

[0086] The epidermis is preferably that of the skin or the scalp.

[0087] According to one embodiment, the epidermis is a sensitive epidermis.

[0088] Skin inflammation is also known as dermatitis or dermatitis.

[0089] Thus, according to one embodiment, the present invention relates to hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins for their topical use for the prevention or treatment of symptoms of skin inflammation.

[0090] Prevention of symptoms of skin inflammation means preventing the occurrence of the four symptoms of skin inflammation, but also delaying the occurrence of the four symptoms of skin inflammation, as well as preventing the worsening of the four symptoms of skin inflammation.

[0091] Treatment of the symptoms of skin inflammation means the disappearance of the four symptoms of skin inflammation, or at least the reduction in the intensity of the four symptoms of skin inflammation, for example the reduction in the intensity of redness and heat and of swelling and pain.

[0092] Non-pathological causes

[0093] The cause(s) of the appearance of one or all of the symptoms, chosen from redness, heat, swelling and pain, are numerous.

[0094] Thus, the at least one symptom is induced by at least one of the conditions chosen from infectious agents, chemical products, ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary, domestic use (for example detergents), mechanical aggressions, environmental factors, aggressions thermal, food and drinks. Another non-pathological cause could be a therapeutic treatment administered orally or intravenously generating one or more secondary cutaneous reactions.

[0095] Among the infectious agents, we can cite bacteria, yeasts, molds, parasites, viruses, even mites, lice and insects when they attack the skin by stings or bites. As an illustration, we can cite ringworm caused by parasites.

[0096] Mechanical aggressions include friction, brushing, shaving, cuts, micro-cuts, physical aggression, hair removal, abrasion, exfoliation, frequent washing, hard water with a high concentration of limestone, etc.

[0097] Friction can be that of clothing on the skin or of skin on skin. For example, clothing made of wool or clothing worn close to the skin, such as socks or scarves, rub against the skin, and can thus generate skin irritation. Friction can also be due to prolonged wearing of helmets, masks, in particular surgical masks, protection against the climate, protection against micro-organisms such as bacteria or viruses, protection against chemicals or solvents or even against dust.

[0098] Abrasion means bringing the skin or mucous membranes into contact with abrasive agents, i.e. solid particles, generally irregular in shape and not smooth. For the skin, the abrasive agents can be gravel, sand, magnesia. For the oral mucous membranes, the abrasive agents can be calcium carbonate.

[0099] Brushing means the action of a brush, in particular the action of a toothbrush on the gums.

[0100] Environmental factors include pollution, sun exposure, radiation such as X-rays and UV radiation, cold, wind, dryness, humidity, etc.

[0101] Among the thermal attacks we will cite, overexposure to the sun, exposure near a source of heat or cold, ...

[0102] Foods or beverages include spices, dairy products, dried fruits, nuts, pineapples, acidic foods, vinegar, alcohol, etc.

[0103] Among the chemical products, mention may be made of irritant or polluting agents such as detergents, pollution, cigarette smoke, household products, and in particular household cleaning products.

[0104] Among the ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary, or domestic use, mention will be made of cosmetic active ingredients, dermatological active ingredients, surfactants, solvents, preservatives, perfumes, acids, exfoliants, detergents.

[0105] These active ingredients with irritant potential have been described in document FR2902998. Thus, as dermatological or cosmetic active ingredients, we can cite certain desquamating agents which can also be peeling agents.

[0106] Among the specifically peeling agents, mention may be made of abrasive / exfoliating particles from mineral, organic, natural or synthetic sources. More particularly, mention may be made of pumice stone particles, silica, polyethylene beads, nylon and fruit stone powders.

[0107] Among these desquamating agents, the following are likely to cause skin irritation: saturated (acetic acid) and unsaturated monocarboxylic acids, saturated and unsaturated dicarboxylic acids, saturated and unsaturated tricarboxylic acids; α-hydroxy acids and [3-hydroxy acids of monocarboxylic acids; α-hydroxy acids and [3-hydroxy acids of dicarboxylic acids; α-hydroxy acids and [3-hydroxy acids of tricarboxylic acids, keto acids, α-keto acids, [3-keto acids of polycarboxylic acids, polyhydroxymonocarboxylic acids, polyhydroxy bicarboxylic acids and polyhydroxy tricarboxylic acids. Particularly among the α-hydroxy acids or their esters, we can cite: glycolic acids, dioic acids such as octadecene dioic acid, citric, lactic, tartaric, malic or mandelic acids, their esters such as dialkyl tartrate (C12 / C13), branched C12-13 tri-alcohol citrate.

[0108] Among the [3-hydroxy acids] we can cite: salicylic acid and its derivatives (including n-octanoyl 5-salicylic acid).

[0109] Among the α-keto acids, we can cite ascorbic acid and its derivatives.

[0110] Among the other desquamating agents we can cite: pyruvic, gluconic acids, glucuronic, oxalic, malonic, succinic, acetic, gentisic, cinnamic, azelaic; phenol; resorcinol; urea and its derivatives, hydroxyethyl urea; oligofucoses; jasmonic acid and its derivatives; ascorbic acid and its derivatives, trichloroacetic acid; Saphora japonica extract and resveratrol.

[0111] Among the desquamating agents, those capable of acting on the enzymes involved in the desquamation or degradation of corneodesmosomes may also be likely to cause skin irritation.

[0112] Among these, we can notably cite chelating agents for mineral salts such as EDTA; N-acyl-N,N',N'ethylene diaminetriacetic acid; aminosulfonic compounds and in particular (N-2 hydroxyethylpiperazine-N-2-ethane) sulfonic acid (HEPES); derivatives of 2-oxothiazolidine-4-carboxylic acid (procysteine); derivatives of alpha amino acids of the glycine type; honey; derivatives sugars such as O-octanoyl-6-D-maltose, O-linoleyl-6-D-glucose and N-acetyl glucosamine.

[0113] Retinoids are also compounds that can cause skin irritation. Examples include retinol and its esters, retinal, retinoic acid and its derivatives, and adapalene.

[0114] Salts and derivatives, such as cis or trans forms, racemic mixtures, dextrorotatory or levorotatory forms of the compounds mentioned above are also considered to be compounds capable of causing skin irritation.

[0115] Other dermatological or cosmetic active ingredients likely to cause skin irritation are also mentioned below: -urea and its derivatives such as hydroxyethyl urea, - certain vitamins such as vitamin D and its derivatives such as vitamin D3, vitamin D2, calcitriol, calcipotriol, tacalcitol, 24,25-diOH vitamin D3, 1-OH vitamin D2 and 1,24-diOH vitamin D2; vitamin B9 and its derivatives, - peroxides such as benzoyl peroxide, hydrogen peroxide, - hair loss medications such as minoxidil and its derivatives such as aminexyl, - hair dyes and colorants such as aminophenols and their derivatives such as para-phenylenediamine (p-PDA), N-phenyl p-PDA, toluene 2,5-diamine sulfate, meta-phenylenediamine (m-PDA), toluene 3,4-diamine and ortho-phenylenediamine (o-PDA), - antiperspirant agents such as aluminum salts, such as aluminum hydroxychloride, - deodorants, - depilatory and / or permanent active ingredients such as thioglycolates, ammonia, - thioglycolate and its salts, - phenoxyethanol, - 1,2-pentanediol, - alcoholic perfume solutions (perfumes, eau de toilette, aftershave, deodorants) - anthralins (dioxyanthranol), - anthranodes - lithium salts, - depigmenting agents (e.g. hydroquinone, high concentration vitamin C, kojic acid), - certain slimming active ingredients with a heating effect, - nicotinates and their derivatives, - capsaicin, anti-lice active ingredients (pyrethrin), - antiproliferative drugs such as 5-fluorouracil or methotrexate, - antiviral agents, - antiparasitics, - antifungals, - antipruritics, - antiseborrheics, - certain sunscreens, - propigmentants such as psoralens and methylangecilins, and - their mixtures.

[0116] As preservatives, mention may be made of propionic acid, calcium propionate, formaldehyde, paraformaldehyde, o-phenylphenol or its salts, zinc pyrithione, sodium, ammonium, potassium sulfites, bisulfites or metabisulfites, chlorobutanol, methylparaben, ethylparaben, propylparaben, butylparaben, formic acid and its salts such as sodium formate, benzoic acid and its salts such as sodium benzoate, sorbic acid and its salts, such as calcium sorbate, sodium sorbate, potassium sorbate, salicylic acid and its salts, dehydroacetic acid and its salts such as sodium dehydroacetate, undecylenic acid and its salts such as calcium undecylenate, undecylenate potassium, sodium undecylenate, phenoxyethanol, l,2-Dimethylol-5,6-dimethylhydantoin, benzyl alcohol, chlorhexidine, chlorhexidine diacetate, chlorhexidine digluconate,chlorhexidine dihydrochloride, behentrimonium chloride, cetrimonium chloride, cetrimonium bromide, laurtrimonium chloride, laurtrimonium bromide, steartrimonium chloride, steartrimonium bromide, hexamidine, hexamidine diisethionate, chlorphenesin, benzalkonium chloride, benzalkonium bromide, benzalkonium saccharin, ethyl lauroyl arginate.

[0117] As surfactants, mention may be made of anionic, cationic and amphoteric surfactants, more particularly anionic surfactants such as alkyl sulfates and alkyl ether sulfates such as lauryl sulfate and lauryl ether sulfate, and their salts, in particular sodium salts.

[0118] According to a preferred embodiment of the invention, the compound capable of causing skin irritation is chosen from surfactants, bases and acids. The acids may be chosen from citric acid, lactic acid, acetic acid, dehydroacetic acid, formic acid, gluconic acid, succinic acid, salicylic acid, glucuronic acid, retinoic acid, glycolic acid, phytic acid, ascorbic acid, and levulinic acid. The bases may be chosen from sodium hydroxide, potassium hydroxide, triethanolamine, amino methyl propanol.

[0119] Preferably, the at least one symptom chosen from redness, heat, swelling and pain is induced by chemical products, ingredients contained in cosmetic or dermatological formulations, mechanical attacks, thermal attacks, environmental factors.

[0120] More preferably, the at least one symptom chosen from redness, heat, swelling and pain or skin inflammation is induced by exposure to chemicals or ingredients contained in topical compositions for cosmetic or dermatological use chosen from surfactants, detergents, hair oxidizing or bleaching agents, or is induced by mechanical aggressions chosen from friction, shaving, cuts, micro-cuts, hair removal, abrasion and exfoliation.

[0121] The non-pathological cause(s) of skin inflammation are also numerous. Indeed, skin inflammation can be induced by at least one of the causes previously described and chosen from infectious agents, chemical products, ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary, or domestic use, mechanical aggressions, environmental factors, thermal aggressions, food and beverages, but also by skin irritation, skin corrosion, skin inflammation of endogenous origin, or a combination of these causes.

[0122] Skin irritation Skin irritation includes acute skin irritation (or acute irritant contact dermatitis), cumulative skin irritation (or cumulative irritant contact dermatitis), and phototoxicity (or phototoxic dermatitis).

[0123] "Acute skin irritation" or "acute irritant contact dermatitis" means a reversible local inflammatory response of the skin of a normal living being to a direct injury caused by the single application of a toxic substance, without the intervention of an immunological mechanism.

[0124] "Cumulative skin irritation" or "cumulative irritant contact dermatitis" means reversible irritation resulting from repeated or continuous exposures to materials that do not in themselves cause acute irritation.

[0125] "Phototoxicity" or "phototoxic dermatitis" means irritation resulting from light-induced molecular changes in the structure of chemicals applied to the skin.

[0126] Thus, according to one embodiment, the skin irritation is selected from cumulative irritant contact dermatitis, acute irritant contact dermatitis and phototoxic dermatitis.

[0127] According to a preferred embodiment, the skin irritation is cumulative irritant contact dermatitis.

[0128] "Skin corrosion" means the direct chemical action on normal living skin which results in its disintegration and irreversible deterioration at the point of contact. Corrosion manifests itself by ulceration and necrosis with subsequent scar formation.

[0129] According to one embodiment, the phototoxicity is induced by the chemicals, the ingredients contained in topical compositions for cosmetic or dermatological use.

[0130] According to a preferred embodiment, skin inflammation is induced by exposure to chemicals and ingredients contained in topical compositions for cosmetic or dermatological use, mechanical attacks, thermal attacks.

[0131] According to a preferred embodiment, the skin inflammation is induced by exposure to chemicals and ingredients contained in topical compositions for cosmetic or dermatological use and preferentially by the ingredients contained in topical compositions for cosmetic or dermatological use.

[0132] The term "skin inflammation of endogenous origin" means inflammation induced by one or more internal biological factors of the human organism, or by one or more pathogenic agents endogenous to the human organism, i.e. pathogenic agents synthesized by the human organism itself.

[0133] Causes of inflammation of the mucous membranes

[0134] According to one embodiment, the invention relates to hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins for their use in the prevention or treatment of symptoms of inflammation of the mucous membranes.

[0135] According to one embodiment, the inflammation is chosen from inflammations of the oral mucosa, preferably inflammation of the oral mucosa by anionic surfactants, or inflammation of the oral mucosa due to irritation caused by toothbrushing. Said anionic surfactants can be applied to the oral mucosa by means of a toothpaste, generally with concomitant brushing, or a mouthwash, generally without concomitant brushing.

[0136] Thus, according to one embodiment, the inflammation of the mucous membranes is induced by ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary, or domestic use such as surfactants or by mechanical aggression such as brushing.

[0137] Pathological causes

[0138] According to one embodiment, the skin inflammation is induced by a dermatological pathology involving an inflammatory process.

[0139] According to one embodiment, the dermatological pathology involving an inflammatory process is chosen from psoriasis, cutaneous atopy, atopic dermatitis, allergic reactions of immediate hypersensitivity type, allergic reactions of delayed hypersensitivity type, inflammatory hyperpigmentations, immune dermatoses, actinic elastosis, alopecia areata, vitiligo, systemic lupus erythematosus, pemphigus vulgaris, dystrophic epidermolysis bulbosa and canities of autoimmune origin, erythemas,

[0140] Among the allergic reactions of the skin of the immediate hypersensitivity type, we will cite urticaria, lucite (or sun allergy), allergies due to exposure to surfactants.

[0141] Among the allergic reactions of the skin of the delayed hypersensitivity type, we will cite contact dermatitis, seborrheic dermatitis, acne, eczema.

[0142] Among the erythemas, we will cite erythemas due to ultraviolet rays, or to friction, or to micro-cuts.

[0143] According to one embodiment, the atopic dermatitis is an atopic dermatitis of sensitive skin.

[0144] Preferably, the dermatological pathologies are chosen from erythema, psoriasis, cutaneous atopy, atopic dermatitis, allergic reactions of immediate hypersensitivity type, allergic reactions of delayed hypersensitivity type, inflammatory hyperpigmentations.

[0145] Preferably, erythemas are due to ultraviolet rays.

[0146] Preferably, the immediate hypersensitivity type allergic reaction is urticaria.

[0147] Preferably, the delayed hypersensitivity type allergic reactions are chosen from contact dermatitis and eczema.

[0148] According to one embodiment, the inflammation of the mucous membranes is induced by a dermatological pathology involving an inflammatory process.

[0149] According to one embodiment, the dermatological pathologies are chosen from pathologies of the oral mucosa, vaginal mucosa, urogenital mucosa, preferentially from pathologies of the oral mucosa.

[0150] According to one embodiment, the pathologies of the oral mucosa are chosen from gingivitis, oral lichen planus, canker sores, etc.

[0151] The terms "prevention" or "treatment" or "prevention method" or "treatment method" are not absolute terms and designate a procedure or a plan of action designed, even with a low probability of success but which must induce an overall beneficial effect such as the disappearance of the pathology, but also the delay in the appearance of the symptoms of the pathology, or the reduction in the severity of one or more symptoms. Typically, in the case of inflammation cutaneous induced by a dermatological pathology involving an inflammatory process, prevention means the prevention of symptoms of the pathology but also the prevention of the worsening of the symptoms of the pathology.

[0152] The present invention also relates to a method for the prevention or treatment of symptoms of skin inflammation induced by a dermatological pathology involving an inflammatory process comprising the administration of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, to a patient in need thereof.

[0153] The present invention also relates to the use of hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, for obtaining a medicament intended for the prevention or treatment of the symptoms of skin inflammation induced by a dermatological pathology involving an inflammatory process.

[0154] The present invention also relates to a composition comprising hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, for their therapeutic use for the prevention or treatment of the symptoms of skin inflammation induced by a dermatological pathology involving an inflammatory process.

[0155] Prevention and / or reduction of the irritant effect of chemical products or ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary, or domestic use.

[0156] According to one embodiment, the invention relates to the use of hyperbranched dextrins, preferably hyperbranched and hydrogenated, to prevent, reduce or eliminate the irritant effect of chemical products coming into contact with the skin and mucous membranes, or of ingredients applied topically, contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary or domestic use.

[0157] An irritant effect means the appearance of at least one symptom at the level of the epithelial tissue or the mucous membranes, chosen from redness, heat, swelling and pain following exposure of the skin or the mucous membrane to one or more chemical products, or following the topical application of cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary, or domestic compositions, comprising ingredients which are irritants for the epithelial tissues or the mucous membranes.

[0158] Hyperbranched dextrins, preferably hyperbranched and hydrogenated, may be applied before or after the use of these ingredients or active ingredients having an irritant effect in order to prevent, significantly reduce or even eliminate this irritant effect. In these two cases, hyperbranched dextrin, preferably hyperbranched and hydrogenated, will be in a topical formulation for cosmetic, dermocosmetic or dermatological, pharmaceutical, medicinal, or veterinary use, which, in fact, will not contain any ingredient or active ingredient having an irritant effect.

[0159] The presence of hyperbranched dextrins, preferably hyperbranched and hydrogenated, in a topical composition for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary, or domestic use, preferably in a topical composition for cosmetic, dermocosmetic, or dermatological use, comprising one or more ingredient(s) or active ingredient(s) having an irritant effect also makes it possible to significantly reduce, or even eliminate, this irritant effect. This also makes it possible to increase the quantity of product with an irritant side effect compared to the quantity of product normally used, with a view to improved effectiveness.This also allows the administration of products with an irritating effect to sensitive skin.

[0160] Topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medicinal, veterinary or domestic use may in fact contain one or more ingredients or active ingredients capable of causing skin irritation, such as cosmetic or dermatological active ingredients, surfactants, solvents, preservatives, perfumes, detergents.

[0161] These ingredients or active ingredients with irritant potential are as previously described.

[0162] Dermatological composition - or dermatologically acceptable composition

[0163] Hyperbranched dextrins, preferably hyperbranched and hydrogenated, may be incorporated into a dermatological composition, or more generally into any composition made of a dermatologically acceptable medium and being brought into contact with an epithelial tissue chosen from keratinized multi-stratified squamous epithelium, non-keratinized multi-stratified squamous epithelium, stratified columnar epithelium, ciliated or non-ciliated pseudo-stratified columnar epithelium, preferably, preferably being brought into contact with the epidermis, the oral cavity, the oral mucosa, the vaginal mucosa, the nostrils, the nasal mucosa, and all preferentially being brought into contact with the skin or the oral mucosa.

[0164] Thus, the present invention also relates to a composition, dermatological or dermatologically acceptable, comprising hydrogenated and hyperbranched dextrins and a dermatologically acceptable medium.

[0165] The term “dermatologically acceptable composition” or “dermatologically acceptable” means any composition which does not present, or very rarely, deleterious side effects and in particular which does not produce unacceptable redness, heating, tightness or tingling, or more generally inflammation, for a user who brings into contacting said dermatologically acceptable composition with an epithelial tissue, preferably with its skin or its mucous membranes. The dermatologically acceptable composition is thus compatible with human epithelial tissues, and the mucous membranes of human beings. Dermatologically acceptable compositions include pharmaceutical, medicinal, and domestic compositions including detergent compositions.

[0166] The composition according to the invention may also be another topical composition intended to treat or care for, preventively or curatively, at least one epithelial tissue chosen from keratinized multi-stratified squamous epithelium (epidermis), non-keratinized multi-stratified squamous epithelium (oral cavity, vaginal mucosa), stratified columnar epithelium (nostrils, conjunctival cul-de-sac), ciliated or non-ciliated pseudostratified columnar epithelium (nasal mucosa). Consequently, this composition may be a topical composition for dermatological, pharmaceutical, medicinal or veterinary use, for the care of the skin and epithelial tissues.

[0167] Galenic

[0168] The dermatological composition according to the invention can be presented in all the galenic forms normally used for topical application such as aqueous, hydroalcoholic or oily solutions, solutions or dispersions of the lotion or serum type, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or suspensions or emulsions, of soft, semi-solid or solid consistency, of the cream, aqueous or anhydrous gel type, anhydrous compositions, solid compositions of microemulsions, microcapsules, microparticles, or vesicular dispersions of the ionic and / or non-ionic type.

[0169] These compositions are prepared by the usual methods known to those skilled in the art.

[0170] The composition may be applied before, during or after the appearance of at least one symptom chosen from redness, heat, swelling and pain, or skin or mucous membrane inflammation, and this application may be repeated or renewed as necessary.

[0171] This composition, when applied to the skin, may be more or less fluid and have the appearance of a cream, an emulsion or microemulsion, an ointment, a milk, a lotion, a serum, a paste, a mousse, a mask, a fluid, a balm, an oil, a gel, an ointment. It may optionally be applied to the skin in the form of an aerosol. It may also be in solid form, for example in the form of a stick or patch, dry soaps, cleansing bars.

[0172] It can be used as a care product, in particular for leave-on application, such as a day or night care cream for the skin of the face and / or body, as a cleaning product, as a makeup product, as a deodorant product, as a shaving product, as an aftershave product, as an after-sun product, as a sun protection product, or as a lip balm protecting the lips from the cold and / or the sun and / or the wind.

[0173] The composition according to the invention may also be a composition for scalp and hair care and may be in galenic forms for rinse-off application, known as "rinse-off" in English, or for non-rinse application. Examples of these forms are shampoos, hair conditioners, hair masks, serums, mousses, balms, creams, sprays, conditioners, detanglers, hair creams and also in the form of a treatment lotion, a dye composition, a coloring shampoo, a perm composition, an anti-hair loss lotion or gel, an anti-parasitic shampoo, or a conditioner.

[0174] The amount of hyperbranched dextrins in the compositions may vary so as to administer an effective amount of hyperbranched dextrins to achieve the desired therapeutic response for a particular patient.

[0175] By "effective amount" or "therapeutically effective amount" of a compound is meant a non-toxic but sufficient amount of the compound to provide the desired effect.

[0176] Typically, the amount administered or dose depends on the activity of the hyperbranched dextrins, the route of administration, the severity of the pathology, as well as the health status and medical history of the patient being treated, various factors such as body weight, diet, and possible combination with other therapeutic agents. However, it is within the skill of the person skilled in the art to determine the appropriate dosage and to initiate treatment at a dosage lower than that required to achieve the desired therapeutic effect and to gradually increase the dose until the desired effect is achieved.

[0177] According to one embodiment, the content of hyperbranched dextrins ranges from 0.5 to 50% by weight, preferably from 1 to 25% by weight, more preferably from 1 to 15% by weight, even more preferably from 2 to 10% by weight, relative to the total weight of the cosmetic, dermatological or dermatologically acceptable composition.

[0178] Formulation ingredients

[0179] According to one embodiment, the hyperbranched dextrins are administered topically.

[0180] Hyperbranched dextrins may be administered in several doses.

[0181] The dermatological composition or topical formulation according to the invention may also comprise a solvent chosen according to the different ingredients and the form of administration.

[0182] According to one embodiment, the composition according to the invention may comprise an aqueous phase comprising water and optionally, one or more water-miscible organic solvents.

[0183] By "water-soluble solvent" is meant a compound that is liquid at room temperature and miscible with water (miscibility in water greater than 50% by weight at 25°C and atmospheric pressure).

[0184] The water-soluble solvents that can be used in the compositions according to the invention can be volatile.

[0185] Among the water-soluble solvents which can be used in the compositions in accordance with the invention, mention may be made of mono-alcohols having from 1 to 5 carbon atoms such as ethanol and isopropanol, C3-C4 ketones and C2-C4 aldehydes and polyols such as glycerol or glycerin, sorbitol or isosorbide.

[0186] The cosmetic composition may also comprise, in addition to hydrogenated and highly branched dextrins:

[0187] - One or more humectant(s):

[0188] The humectant(s) will be chosen from polyols and / or esters of fatty acids and polyethylene glycol.

[0189] By “polyols” is meant any molecule having in its structure at least two free hydroxyl (-OH) groups. These polyols are preferably liquid at room temperature (25°C).

[0190] Typically, the polyol will be chosen from maltitol, mannitol, xylitol, erythritol, sorbitol, isosorbide, glycerol or glycerin, glucose, sucrose, polydextrose, hydrogenated glucose syrups, dextrins, maltodextrins, glucose syrups, and mixtures thereof.

[0191] By way of illustration, mention may be made of the product Beauté by Roquette® PO 071 (INCI: Sorbitol), the product Beauté by Roquette® PO 260 (INCI: Mannitol), the product Beauté by Roquette® PO 370 (INCI: Xylitol), the product Beauté by Roquette® PO 455 (INCI: Hydrogenated starch hydrolysate), the product Beauté by Roquette® PO 500 (INCI: Isosorbide), all marketed by the company ROQUETTE, glycerin (INCI: glycerin) sold by the company COOPER, propylene glycol (INCI: propylene Glycol) from the company COOPER, Butylene Glycol (INCI: 1,3-BUTANEDIOL)

[0192] Among the esters of fatty acids and polyethylene glycol, mention will be made of the product sold under the name Glucamate SSE-20 (INCI: PEG-20 METHYL GLUCOSE SESQUISTEARATE) by the company LUBRIZOL ADVANCED MATERIALS, Inc.

[0193] The composition comprises from 0.5 to 25% by weight of one or more humectants, preferably from 1 to 15% by weight, and even more preferably from 2 to 10% by weight of polyols, relative to the total weight of the composition.

[0194] - One or more oil(s)

[0195] For the purposes of the present invention, the term "oil" means a compound which is liquid at room temperature (25°C), and which, when introduced at a rate of at least 1% by weight into water at 25°C, is not at all soluble in water, or soluble to a level of less than 10% by weight, relative to the weight of oil introduced into the water.

[0196] According to one embodiment, the oil will be chosen from volatile oils, non-volatile oils and their mixtures. Preferably, these oils are vegetable or of vegetable origin.

[0197] The term “non-volatile oil” means an oil remaining on keratin materials at room temperature and atmospheric pressure for at least several hours and in particular having a vapor pressure of less than 103 mm Hg (0.13 Pa).

[0198] Among the non-volatile oils, mention may be made of fatty esters such as cetearyl isononoate, isotridecyl isononoate, isostearyl isostearate, isopropyl isostearate, isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, isononyl isononate, 2-ethylhexyl palmitate, 2-hexyldecyl laurate, 2-octyl decyl palmitate, 2-octyldodecyl myristate or lactate, 2-diethylhexyl succinate, diisostearyl malate, tracetin, tricprin, caprylic / capric acid triglycerides, coco caprate and caprylate mixture, C12-C15 alcohol benzoates, glycol esters such as butylene glycol cocoate, glycerin triisostearate, tocopherol acetate, higher fatty acids such as myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid or isostearic acid,higher fatty alcohols such as oleyl alcohol, vegetable oils such as avocado oil, camellia oil, hazelnut oil, tsubaki oil, cashew nut oil, argan oil, soybean oil, grape seed oil, sesame oil, corn oil, wheat germ oil, rapeseed oil, sunflower oil, cottonseed oil, jojoba oil, peanut oil, macadamia oil, sweet almond oil, olive oil and mixtures thereof.

[0199] These non-volatile oils can also be hydrocarbon or silicone type oils such as paraffin oil, squalane, petroleum jelly, dimethyl siloxanes and mixtures thereof.

[0200] According to one embodiment, the non-volatile oil is chosen from stearic acid, jojoba oil (INCI: simmondsia Chinensis Seed Oil), grape seed oil (INCI: vitis vinifera seed oil), macadamia oil (INCI: Macadamia temifolia seed oil), refined oleic sunflower oil (Helianthus annuus seed oil), the mixture of coco caprate and caprylate such as the product Miglyol Coco 810 (INCI: Coco-Caprylate / Caprate), sweet almond oil (INCI: Prunus Amygdalus Dulcis Oil), sesame oil (INCI: Sesamum indicum seed oil).

[0201] By volatile oil is meant an oil capable of evaporating from the skin in less than one hour at room temperature and atmospheric pressure. Volatile oils may be chosen, for example, from silicone oils or short fatty acid triglycerides to reduce the greasy feel.

[0202] According to one embodiment, the oil(s) is / are present in a content ranging from 0.5 to 70% by weight, preferably from 1 to 60% by weight, preferably from 2 to 50% by weight, preferably from 5 to 40% by weight, preferably from 5 to 30% by weight relative to the total weight of the composition.

[0203] - One or more wax(es) and / or one or more pasty compound(s).

[0204] By "wax" is meant a fatty substance with a reversible liquid / solid state change, having a melting point above 25°C, generally between 30°C and 90°C, which can be made liquid under the conditions of preparation of the composition and has an anisotropic crystalline organization in the solid state. The waxes used according to the invention may consist of polar or apolar waxes or a mixture of the two. By "apolar" is meant a wax containing only carbon, hydrogen and / or phosphorus atoms and in particular a hydrocarbon.

[0205] Polar waxes may in particular be chosen from animal waxes, vegetable waxes and synthetic or silicone waxes containing polar groups such as esters. Mention may thus be made of Camauba wax, Candelilla wax, bee wax (Cera alba), Chinese insect wax (Ericerus pela), Japanese wax, Sumac wax, Montan wax, C8-C20 acid triesters and glycerin wax such as glycerin tribehenate, acetylated glycol stearate marketed in particular by the company VEVY under the trade name CETACENE, and mixtures thereof. These waxes may in particular be used in predispersed form in an oil, as is the case with the mixture of candelilla wax and jojoba seed oil. Preferably, these waxes are vegetable or of vegetable origin.

[0206] According to one embodiment, the wax or waxes is / are present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, preferably from 5 to 10% by weight, relative to the total weight of the composition.

[0207] The term “pasty compound” means lipophilic fatty substances which, like waxes, are capable of undergoing a reversible liquid / solid state change and have an anisotropic crystalline organization in the solid state, but which differ from waxes in that they contain, at a temperature of 23°C, a liquid fraction and a solid fraction. These pasty compounds are preferably vegetable butters or butters of vegetable origin, such as shea butter or camellia butter.

[0208] According to one embodiment, the pasty compound(s) is / are present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, preferably from 5 to 10% by weight, relative to the total weight of the composition.

[0209] - One or more gelling agent(s)

[0210] By gelling agent is meant a compound which, in the presence of a solvent, creates more or less strong inter-macromolecular bonds, thus inducing a three-dimensional network which freezes said solvent. By gelling agent is also meant thickening or rheological agents, acting on the viscosity and flow properties of an aqueous phase or a fatty phase.

[0211] The gelling agent makes it possible in particular to increase the viscosity of the continuous phase, for example to adjust the viscosity of the continuous phase to a value ranging from 100 mPa.s to 20,000 mPa.s.

[0212] The gelling agent may be chosen from polymers of synthetic origin or of plant origin, preferably of plant origin, chemically modified or not.It can thus be chosen from gums derived from plants such as gum arabic, konjac gum, guar gum or their derivatives, gums extracted from algae such as alginates; gums derived from microbial fermentation such as xanthans, for example, the product Keltrol CG (INCI: xanthan gum), sold by the company CP KELCO or the product Xanthan Gum FNCS-PC (INCI: xanthan gum) sold by the company JUNGBUNZLAUER INTERNATIONAL AG, mannans, scleroglucans or their derivatives; cellulose and its derivatives such as carboxymethylcellulose or hydroxyethylcellulose; starch and its derivatives such as in particular native starches and modified starches, in particular pregelatinized, acetylated, hydroxypropylated, carboxymethylated, cationic, octenylsuccinate, crosslinked, possibly several times modified starches; synthetic polymers such as polyacrylic acids or carbomers, and mixtures thereof.

[0213] Among the starches and starch-based mixtures, mention may be made of the product Beauté by Roquette® ST 118 (INCI: Carboxymethyl starch), the product Beauté by Roquette® ST 720 (INCI: Hydroxypropyl starch) and the product Beauté by Roquette® DSI 12 (INCI: Starch acetate (and) Hydroxyethylcellulose (and) Xanthan gum), all sold by the company Roquette.

[0214] Among the carbomers, we will cite for example the product Carbopol Ultrez 30 (INCI: carbomer) from the company LUBRIZOL ADVANCED MATERIALS, Inc. or CARBOPOL ETD 2050 POLYMER (INCI: carbomer).

[0215] Mention will also be made of mixtures of gum arabic and xanthan gum such as the product Solagum AX (INCI: Acacia Senegal Gum (and) Xanthan Gum), sold by the company SEPPIC, mixtures of starch and cellulose derivatives such as the product Beauté by Roquette® DS 112 (INCI: Starch acetate (and) Hydroxyethylcellulose (and) Xanthan gum), sold by the company ROQUETTE.

[0216] The gelling agent may be a mineral gelling agent selected from magnesium and / or aluminum silicates. An example of such a mineral gelling agent is Veegum® Pure from Vanderbilt Minerals LLC, which is a magnesium aluminum silicate.

[0217] According to one embodiment, the gelling agent(s) is / are present in a content ranging from 0.1 to 50% by weight, preferably from 0.5 to 25% by weight, preferably from 0.3 to 15% by weight, relative to the total weight of the composition.

[0218] - One or more binder(s)

[0219] The term "binder" means compounds that provide increased cohesion to the cosmetic composition. This cohesion can be adjusted depending on the quantity and chemical affinity of the binding agent relative to the ingredients of the cosmetic composition.

[0220] Typically, the binder will be chosen from caprylic / capric acid triglycerides such as the product Labrafac CC (INCI: capric / caprylic triglicerides) or Cetyl Dimethicone (INCI).

[0221] The binder(s) is / are present in the composition according to the invention at a content ranging from 0.5% to 20%, preferably from 1 to 15%, preferably from 5 to 12%, by weight relative to the total weight of the composition.

[0222] - One or more emulsifying agent(s)

[0223] The cosmetic composition according to the invention may also comprise one or more oil-in-water (O / W) or water-in-oil (W / O) emulsifiers.

[0224] The oil-in-water (O / W) emulsifier is an emulsifying agent with an HLB greater than or equal to 8 and chosen from optionally polyethoxylated sorbitan esters, fatty acid esters of glycerol, fatty acid esters or polyesters of sucrose, fatty acid esters of polyethylene glycol, polyether-modified polysiloxanes, fatty alcohol ethers of polyethylene glycol, alkylpolyglycosides and hydrogenated lecithin, fatty alcohols, sorbitan esters without this list being limiting, and mixtures thereof.

[0225] By way of illustration, we will mention the product Montanov 68 (INCI: CETEARYL ALCOHOL (AND) CETEARYL GLUCOSIDE), marketed by the company SEPPIC, the product Montanov L (INCI: C14-C22 Alcohols & C12-20 Alkyl Glucoside), marketed by the company SEPPIC, Montanov 202 (INCI: Arachidyl Alcohol (and) Behenyl Alcohol (and) Arachidyl Glucoside), Citrol GMS 40 (INCI: Glyceryl stearate), sold by the company CRODA, or the product Imwitor 960K (INCI: Glyceryl stearate), sold by the company BIESTERFELD, the product Imwitor 372P (INCI: Glyceryl stearate citrate), sold by the company BIESTERFELD, the product Glucate SS (INCI: Methyl Glucose Sesquistearate), sold by LUBRIZOL ADVANCED MATERIALS, Inc., stearic plurol (Polyglyceryl-6 Distearate), Natragem E145 (INCI: Polyglyceryl-4 Laurate / Succinate (and) Aqua), sold by CRODA, Span 60 product (INCI: sorbitan stearate), sold by SIGMA ALDRICH.

[0226] Among the sorbitan esters, we will cite for example the product Span 20.

[0227] Among the fatty alcohols, we will cite for example the product sold under the name Promulgen D (INCI: Cetearyl alcohol (and) Ceteareth-20).

[0228] The H / W emulsifier may advantageously be chosen from emulsifying systems composed of a cyclodextrin and a water-in-oil emulsifier of natural origin, such as the emulsifying system marketed by Roquette Frères under the name Beauté by Roquette® DS 146, or from emulsifying systems based on modified starches and vegetable gums, such as Beauté by Roquette® DS 421 sold by the applicant.

[0229] The water-in-oil (W / O) emulsifier is an emulsifying agent with an HLB of less than 8 and chosen from non-ethoxylated fatty esters of polyols, and in particular from non-ethoxylated fatty esters of glycerol, polyglycerols, sorbitol, sorbitan, anhydrodrohexitols such as in particular isosorbide, mannitol, xylitol, erythritol, maltitol, sucrose, glucose, polydextrose, hydrogenated glucose syrups, dextrins and hydrolyzed starches.

[0230] The emulsifying agent(s) is / are present in the composition according to the invention at a content ranging from 0.5% to 20%, preferably from 1 to 15%, preferably from 2 to 12%, by weight relative to the total weight of the composition.

[0231] One or more surfactants

[0232] According to one embodiment, the composition according to the invention comprises at least one surfactant chosen from ionic, non-ionic, anionic, cationic or amphoteric or zwitterionic surfactants. These surfactants are chosen for their detergent and foaming function.

[0233] According to another embodiment, the composition according to the invention comprises at least one surfactant chosen from anionic surfactants, amphoteric or zwitterionic surfactants.

[0234] The anionic surfactants are chosen from carboxylic anionic surfactants, sulfated anionic surfactants, sulfonate surfactants, phosphate anionic surfactants, and mixtures thereof, preferably from sulfonate anionic surfactants, carboxylic anionic surfactants, and mixtures thereof.

[0235] By "anionic surfactant" is meant a surfactant comprising only anionic groups as ionic or ionizable groups. In the present description, an entity is described as being "anionic" when it has at least one permanent negative charge or when it can be ionized into a negatively charged entity, under the conditions of use of the composition of the invention (medium, pH for example) and not comprising a cationic charge. By "sulfated anionic surfactant" is meant an anionic surfactant comprising at least one sulfate function (-OSO3H or -OSO3), and possibly also comprising one or more other functions derived from acids, such as carboxylic acid or carboxylate functions (-COOH or -COO), sulfonate functions (-SO3H or -SO3) and / or phosphate functions. By way of example, alkyl sulfates, alkyl ether sulfates, alkylamido ether sulfates, alkylaryl polyether sulfates, monoglyceride sulfates, as well as the salts of these compounds, are sulfated anionic surfactants.The alkyl groups of these exemplary compounds contain from 6 to 30 carbon atoms, and the aryl group denotes a phenyl or benzyl group. These exemplary compounds may be polyoxyalkylenated, in particular polyoxyethylenated, and contain from 1 to 50 ethylene oxide units. The term "non-sulfated anionic surfactant" means a surfactant which does not fall within the definition of "sulfated anionic surfactant" as defined above.

[0236] It is also understood according to the invention that: - carboxylic anionic surfactants comprise at least one carboxylic or carboxylate function (-COOH or -COO), but do not comprise a sulfonic or sulfonate function (-SO3H or -SO3), nor a sulfate function (-OSO3H or -OSO3); - the anionic sulfonate surfactants comprise at least one sulfonic or sulfonate function (-SO3H or -SO3 ), and may optionally further comprise one or more carboxylic or carboxylate functions (-COOH or -COO ) and / or phosphates, but do not comprise a sulfate function (-OSO3H or -OSO3 ). - the anionic phosphate surfactants comprise at least one phosphoric or phosphate function (-OPO3H2 or -OPO32 ), but do not comprise a carboxylic or carboxylate function (-COOH or -COO ), nor a sulfonic or sulfonate function (-SO3H or -SO3 ), nor a sulfate function (-OSO3H or -OSO3 ).

[0237] In other words:

[0238] - an anionic surfactant comprising at least one sulfate function (-OSO3H or - OSO3), and at least one carboxylic or carboxylate function (-COOH or -COO), is considered, within the meaning of the invention and unless otherwise indicated, as a sulfated anionic surfactant;

[0239] - an anionic surfactant comprising at least one sulfate function (-OSO3H or -OSO3), and at least one sulfonic or sulfonate function (-SO3H or -SO3), is considered, within the meaning of the invention and unless otherwise indicated, as a sulfated anionic surfactant;

[0240] - an anionic surfactant comprising at least one sulfonic or sulfonate function (-SO3H or -SO3 ), and at least one carboxylic or carboxylate function (-COOH or -COO ), is considered, within the meaning of the invention and unless otherwise indicated, as a non-sulfated sulfonate anionic surfactant; • an anionic surfactant comprising at least one sulfate function (-OSO3H or -OSO3 ), and at least one sulfonic or sulfonate function (-SO3H or -SO3 ), and at least one carboxylic or carboxylate function (-COOH or -COO ), is considered, within the meaning of the invention and unless otherwise indicated, as a sulfated anionic surfactant.

[0241] The carboxylic anionic surfactants may be chosen from the following compounds: acylglycinates, acyllactylates, acylsarcosinates, acylglutamates; alkyl-D-galactoside-uronic acids, alkyl ether carboxylic acids, alkyl(aryl) ether carboxylic acids, alkylamido ether carboxylic acids; as well as the salts of these compounds. The alkyl and / or acyl groups of these compounds comprise from 6 to 30 carbon atoms, more preferably from 8 to 28, more preferably still from 10 to 24, even better still from 12 to 22, carbon atoms. The aryl group preferably denotes a phenyl or benzyl group. These compounds may be polyoxyalkylenated, in particular polyoxyethylenated, and then preferably comprise from 1 to 50 ethylene oxide units, better still from 2 to 10 ethylene oxide units.Also useful are C6-C24 alkyl monoesters of polyglycoside-polycarboxylic acids such as C6-C24 alkyl polyglycosidecitrates, C6-C24 alkyl polyglycoside tartrates, and their salts.

[0242] According to one embodiment, the carboxylic anionic surfactants are chosen from: - acylglutamates, in particular C6 C24, or even C12-C20, such as stearoylglutamates, and in particular sodium or disodium stearoylglutamate or cocoylglutamates, in particular sodium or disodium cocoyl glutamate; - acylsarcosinates, in particular C6 C24, or even C12-C20, such as cocoyl sarcosinates and in particular sodium cocoyl sarcosinate, lauroyl sarcosinates and in particular sodium lauroyl sarcosinate, palmitoylsarcosinates, and in particular sodium palmitoylsarcosinate; - acyllactylates, in particular C12-C28, or even C14-C24, such as behenoyllactylates, and in particular sodium behenoyllactylate, (iso)stearoyl lactylates, and in particular sodium (iso)stearoyl lactylate; - C6-C24 acylglycinates, in particular C12-C20 such as cocoyl glycinates and in particular sodium cocoyl glycinate; - alkyl(C6-C30)ethercarboxylic acids, in particular alkyl(C6-C24)ethercarboxylic acids; - alkyl(C6-C30) aryl ethercarboxylic acids, in particular alkyl(C6-C24) aryl ethercarboxylic acids; - alkyl(C6-C30)amidoethercarboxylic acids, in particular alkyl(C6-C24)amidoethercarboxylic acids; - and their mixtures; and in particular in the form of salts of alkali or alkaline-earth metals, ammonium, or amino alcohol.

[0243] The anionic sulfonate surfactants may be chosen from the following compounds: alkylsulfonates, alkylamidesulfonates, alkylarylsulfonates, C6-C24 alkyl polyglycoside sulfosuccinates, alpha-olefinsulfonates, paraffin sulfonates, alkylsulfosuccinates, alkylethersulfosuccinates, alkylamidesulfosuccinates, alkylsulfoacetates, N-acyltaurates, acylisethionates; alkylsulfolaurates; as well as the salts of these compounds; the alkyl groups of these compounds comprising from 6 to 30 carbon atoms, in particular from 12 to 28, even better from 14 to 24, or even from 16 to 22, carbon atoms; the aryl group preferably denoting a phenyl or benzyl group; these compounds may be polyoxyalkylenated, in particular polyoxyethylenated and then preferably comprising from 1 to 50 ethylene oxide units, better still from 2 to 10 ethylene oxide units.

[0244] According to one embodiment, the anionic sulfonate surfactants are chosen from: C6-C24 alkylsulfosuccinates, in particular C12-C20, in particular laurylsulfosuccinates; C6-C24 alkylethersulfosuccinates, in particular C12-C20; (C6-C24)acylisethionates, preferably (C12-C18)acylisethionates; alpha-olefin-sulfonates; and mixtures thereof; and in particular in the form of alkali or alkaline-earth metal, ammonium, or aminoalcohol salts.

[0245] According to one embodiment, the anionic surfactants may be chosen from C6-C24 alkyl monoesters of polyglycoside dicarboxylic acids such as alkyl glucoside citrates, alkyl polyglycoside tartrates and alkyl polyglycoside sulfosuccinates, alkyl sulfosuccinamates, acylisethionates and N-acyltaurates, the alkyl or acyl group of all these compounds preferably comprising from 12 to 20 carbon atoms. Another group of anionic surfactants usable in the compositions of the present invention is that of acyllactylates whose acyl group comprises from 8 to 20 carbon atoms. In addition, we may also mention alkyl-D-galactosideuronic acids and their salts as well as polyoxyalkylenated (C6-C24 alkyl)ethercarboxylic acids, polyoxyalkylenated (C6-24 alkyl)(C6-C24 aryl)ethercarboxylic acids, polyoxyalkylenated (C6-24 alkyl)amidoethercarboxylic acids and their salts, in particular those comprising from 2 to 50 ethylene oxide units, and mixtures thereof.

[0246] The anionic phosphate surfactants are chosen from: C6-C24 alkyl phosphates, in particular C12-C20; C6-C24 alkyl ether phosphates, in particular C12-C20; and mixtures thereof.

[0247] The amphoteric or zwitterionic surfactants may be chosen from derivatives of secondary or tertiary or quaternary aliphatic amines, in which the aliphatic group is a linear or branched chain comprising from 8 to 22 carbon atoms and containing at least one anionic group such as, for example, a carboxylate, sulfonate, sulfate, phosphate or phosphonate group. Mention may also be made of: alkyl(C8-C20)betaines, for example cocobetaine; sulfobetaines; alkyl(C8-C20)sulfobetaines; alkyl(C8-C20)amidoalkyl(C3-C8)betaines, for example cocamidopropylbetaine; or alkyl(C8-C20)amidoalkyl(C6-C8)sulfobetaines.

[0248] The cationic surfactants can be chosen from Cetrimonium Chloride marketed under the reference Microcare Quat CTC 30.

[0249] The surfactant(s) is / are present in the composition according to the invention at a content ranging from 0.1% to 40%, preferably from 0.5 to 30%, preferably from 1 to 20%, preferably from 2 to 12% by weight relative to the total weight of the composition.

[0250] - One or more film-forming agent(s)

[0251] The film-forming agent may be chosen from polymers of natural origin such as hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), or synthetic polymers such as polyvinyl alcohol (PVA), and / or plasticizers other than polyols, such as polyethylene glycol, triethylcitrate, polysorbate, or even waxes such as Carnauba wax, or hydrogenated castor oil.

[0252] Also mentioned as a film-forming agent of plant origin is hydroxypropylated pea starch Beauté by Roquette® ST 720 as a film-forming agent, sold by the company ROQUETTE.

[0253] The film-forming agent(s) is / are present in the composition according to the invention at a content ranging from 0.1% to 20%, preferably from 0.5 to 15%, preferably from 1 to 12%, by weight relative to the total weight of the composition.

[0254] - One or more coloring matter(s)

[0255] The cosmetic composition according to the invention may also comprise at least one coloring material chosen from water-soluble or liposoluble colorants, fillers having the effect of coloring and / or opacifying the composition and / or coloring keratin materials, preferably skin or hair, such as pigments, pearlescent agents, lakes (water-soluble dyes adsorbed on an inert mineral support), and mixtures thereof. These coloring materials may optionally be surface-treated with a hydrophobic agent such as silanes, silicones, fatty acid soaps, C9-15 fluoroalcohol phosphates, acrylate / dimethicone copolymers, mixed C9-15 fluoroalcohol phosphate / silicone copolymers, lecithins, camauba wax, polyethylene, chitosan and optionally acylated amino acids such as lauroyl lysine, disodium stearoyl glutamate and aluminum acyl glutamate, phytic acid. Another natural colorant is Beauté by Roquette® CC 001 caramel colorant, sold by the company ROQUETTE.

[0256] The term “pigments” means white or colored particles, mineral or organic, intended to color and / or opacify the cosmetic composition.

[0257] Among the pigments, mention will be made of mineral or organic pigments, natural or synthetic. Examples of pigments are in particular iron, titanium or zinc oxides, as well as composite pigments and goniochromatic, pearlescent, interference, photochromic or thermochromic pigments, without this list being limiting.

[0258] Among the pigments surface-treated with lecithins, mention will be made of the products UNIPURE WHITE LC981 HLC (INCI: CI 77891 (and) Hydrogenated Lecithin, UNIPURE YELLOW LC182 HLC (INCI: CI 77492 (and) Hydrogenated Lecithin), UNIPURE BLACK LC989 HLC (INCI: CI 77499 (and) Hydrogenated Lecithin, UNIPURE RED LC381HLC (INCI: CI 77491 (and) Hydrogenated Lecithin) from the company Sensient Cosmetic Technologies.

[0259] Among the pigments surface-treated with phytic acid, mention will be made of the products Unipure White LC 985 PHY (INCI: CI 77891 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Yellow LC 188 PHY (INCI: CI 77492 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Red LC 388 PHY (INCI: CI 77491 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Black LC 998 PHY (INCI: CI 77499 (and) Phytic Acid (and) Sodium Hydroxide), from the company Sensient Cosmetic Technologies.

[0260] The term “mother-of-pearl” means any colored particles, iridescent or not, which exhibit a color effect through optical interference.

[0261] Among the nacres, mention will be made of titanium mica covered with metallic oxide such as iron oxide or titanium oxide.

[0262] According to one embodiment, the makeup and / or care composition according to the invention comprises at least colored particles, preferably pigments such as iron oxide pigments and / or mother-of-pearls.

[0263] The coloring material(s) is / are present in the composition according to the invention at a content ranging from 0.05% to 20%, preferably from 0.1% to 15%, preferably from 0.5 to 12%, by weight relative to the total weight of the composition.

[0264] One or more sensory charge(s) or powder(s) £ s )

[0265] By this term is meant any particle of any shape (in particular spherical or lamellar), mineral or organic, insoluble in the composition. Examples of sensory filler or powder are talc, boron nitride, starch such as the granular starches Beauté by Roquette® ST 005 and Beauté by Roquette® ST 012 sold by the company ROQUETTE, polyamides, silicone resins, silicone elastomer powders and acrylic polymer powders, in particular poly(methyl methacrylate) or styrene acrylate copolymer powders (Sunsphere Powders from Dow).

[0266] The filler(s) is / are present in the composition according to the invention at a content ranging from 0.5% to 20%, preferably from 1 to 15%, preferably from 3 to 12%, by weight relative to the total weight of the composition.

[0267] One or more sensory agent(s)

[0268] Sensory agents make it possible to modify the sensory profile of the cosmetic or dermatological composition, to make it more pleasant to use on the skin. The sensory agents can be chosen from modified starches such as carboxymethyl starches, for example Beauté by Roquette® ST 118 from Roquette, silicas, or talcs, or mixtures thereof. These sensory agents provide softness to the touch for solid compositions, or a cushion effect for compositions in liquid or gel form.

[0269] The sensory agent(s) is / are present in the composition according to the invention at a content ranging from 0.1% to 20%, preferably from 1 to 15%, preferably from 3 to 12%, by weight relative to the total weight of the composition.

[0270] - One or more active ingredient(s)

[0271] In addition to hyperbranched dextrins, the cosmetic composition may comprise one or more active ingredients.

[0272] These active ingredients may be of a very broad chemical nature due to the fact, as the applicant has been able to observe, that hyperbranched dextrin, preferably hyperbranched and hydrogenated dextrin, is rather inert, has low reactivity and very good compatibility with most of the active ingredients used in dermatological compositions / topical formulations. These active ingredients may be chosen from moisturizing, emollient, film-forming, barrier, anti-pollution, tensor, anti-aging, antioxidant, exfoliating, collagen stimulating, anti-acne, sebum reducing, blood circulation stimulating, refreshing, antibacterial, antifungal, anti-inflammatory agents, soothing, anti-irritant, healing, slimming, pigmenting, coloring, mattifying and perfuming.

[0273] Among the soothing agents, those extracted from plants will be preferably used. In particular, soothing agents will be C-glycosides such as those described in document FR2902998.

[0274] Preferably, the hyperbranched dextrins can be combined with another anti-inflammatory cosmetic active ingredient or a soothing active ingredient.

[0275] Among the active ingredients, we can cite those described in the following table:

[0276] [Tables 1] fi? WîSSA? BOB ] SsWOOïBssS BsSÔBsfes Ls£sfe S ] s» W £sî?;Si?ï tes??® sjWwSs LesSfiÇW* M S Cssssssæs Os Êssmf o €®sss®fe æ;sms »WW tW? IVKI ; Lsâ S : SssWs i & te» œ Cx ] : \x x s ; ' S S " — x S fi X s ] -.8 &w s£.»ws sss ysfe» Sassws «O WïB îiB sssàssks wfctaMf» Sssfest&ïssB W: : -OX'? Ss *JS fi, jx.'S SSS Cf ïSSO : Bs-' Os' Bwssssm : us i Sas BssÀSBsss ôs w SS tesSSs i Bsswfem €b s i • s MBsWBswssw r;^v.-?xxv.xM<-.v 3 &SÀSSSS ?.'w £ss>'ses' jSSxSsSSOOS Srcssm go-as? sssBasw ÇxS£SS HxSSKsS SA X? SJ SV. l;sÀs>:'jsSJiï'Ç'XS»J«t^î^S8iS Ast sÆssssssso y' Br-SS AsBj&iW BwSs Bsws s sS4S£àAs?£^ §-Lssxs^ ?~SxS SSSÿA ? OS « SOSsSAA SksA®S:Bi? seM ssss BsÀ'SSKfiÉ^^^^ ■Rmm A Cs. £< &W« sf s.WsssoW XSX ^'X \' XX BSOsfe A :j Bssctesssôsiî A}i£ SS'SSS' Bss a?saisis ssssss £s$M$. Bsssfiss &Â$B Axis. tsS.WâS^S'Ss Sfi?<>&SS£:S$^ CSSSSSBiS: £sSf SAS «? SAïSSBîSSS SSKWB B-Bssos Œ- Gsï BsSf SÀ! “? Assss sssBs C&SYSfi

[0277] The active principle(s) is / are present in the composition according to the invention at a content ranging from 0.05% to 20%, preferably 0.1 to 10%, preferably 0.5 to 6%, by weight of the total composition.

[0278] Dermatological compositions according to the invention are particularly suitable for intolerant and / or irritable skins as well as sensitive scalps

[0279] Irritable or intolerant skin has been defined in patent FR2918886.

[0280] Intolerant skin is skin that reacts with sensations of heating, tightness, tingling and / or redness to various factors such as the application of cosmetic or dermatological products. In general, these signs are associated with erythema and hyperseborrheic or acneic skin, or even rosacea, with or without rashes.

[0281] Irritable skin is skin that reacts with pruritus, that is, itching or tingling, to various factors such as the environment, emotions, food, wind, friction, razors, hard water with a high concentration of limestone, temperature variations or wool. Most often, skin irritability is expressed by visible signs such as skin redness, a feeling of heating of the skin or scalp which can lead to a feeling of pain.

[0282] By "sensitive scalp" we mean scalps for which the sensations of itching and / or tingling and / or heating are essentially triggered by local factors such as friction, soap, surfactants, hard water with a high concentration of limestone, shampoos or lotions. These sensations are also sometimes triggered by factors such as the environment, emotions and / or food. Erythema and hyperseborrhea of ​​the scalp as well as a dandruff condition are frequently associated with the above signs. Examples

[0283] Example 1: In vitro determination of the effect of hyperbranched and hydrogenated dextrins on skin inflammation on a 2D reconstructed human epidermis model

[0284] The objective of the study is to determine the effect of hyperbranched and hydrogenated dextrins on inflammation biomarkers using a two-dimensional (2D) reconstructed human epidermis model after inflammatory pre-treatment. In this example, the hyperbranched and hydrogenated dextrin Nutriose® HM 06 sold by the Applicant was selected.

[0285] Materials and methods

[0286] Reconstructed human epidermis model

[0287] In vitro reconstructed human skin equivalents mimic normal human skin in a very similar way. Since these models reproduce, to a large extent, the barrier function properties of normal human skin, they can be used for screening potential skin irritants. The model used is a two-dimensional reconstruction of the human epidermis, adapted from the method Poumay et al., 2004 (1 Poumay, Y., Dupont, F., Marcoux, S., Leclerk- Smekens, M., Herin, M. And Coquette, A. (2004) A simple reconstructed human epidermis: preparation of the culture model and utilization in in vitro studies. Arch. Dermatol. Res. 296: 203-211). This model comprises a monolayer of normal human epidermal keratinocytes (NHEK, one of the major cell types of the skin), which were cultured on inert polycarbonate inserts.

[0288] The test substances can be applied topically, directly to the surface of the epidermis, and their irritant potential and / or efficacy can be assessed using a number of parameters, including the expression levels of key cellular markers of inflammation.

[0289] Exposure of tissues to samples

[0290] The epidermis were treated with an aqueous solution of Sodium Lauryl Sulfate (SLS) at 0.5% for 6 hours in order to create an inflammation of the reconstructed epidermis, then the surface of the epidermis was rinsed with 500 μL of PBS. 20 μL of the different concentrations of hydrogenated and highly branched dextrins (10 and 5% in ultrapure water) as well as Betamethasone cream at 0.05% (Biogaran cream, is a corticosteroid with an anti-inflammatory role) were applied topically to the epidermis for a period of 20 hours at 37°C. No application was carried out for the SLS control within 20 hours following the PBS rinse.

[0291] The negative control (UTC) followed, under the same conditions, the different technical steps without the application of SLS or sample. Sodium lauryl sulfate (0.5% SLS in water) serves as a positive control for epidermal inflammation.

[0292] MTT cell proliferation test

[0293] Irritating chemical compounds are capable of penetrating the stratum corneum and are cytotoxic to cells in the underlying layers. Cell viability has been shown to be directly correlated with the irritant potential of the chemical compounds. Cell viability is measured upon metabolism by mitochondrial succinic dehydrogenase of the vital dye MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, thiazolyl blue; EINECS number 206-069-5, CAS number 298-93-1)], into a blue formazan salt which is measured quantitatively after its extraction from the tissues.

[0294] The colored solution is measured spectrophotometrically at 570 nm using the Molecular Devices VMAx- microplate reader and the absorbance values ​​are recorded via SOFTmax PRO v4.7.1 software. Statistical analysis is performed using Graph Pad Prism v5.03 software.

[0295] According to the results of this test, - If the viability is less than 50%, then the ingredient is an irritant - If the viability is greater than 50%, then the ingredient is: - mild irritant if it activates inflammation biomarkers; - non-irritating if it does not activate inflammation biomarkers.

[0296] Assay of inflammation markers

[0297] Interleukins IL-1a and IL-8 and tumor necrosis factor-a (TNF-a) are measured to determine whether or not the treatment has induced an inflammatory reaction in the treated tissue.

[0298] For this, the cell supernatants are collected after the required treatment time and commercially available ELISA kits are used to quantitatively determine the presence of inflammation markers.

[0299] [Tables2] Marker dosed ELISA kit used Supplier Reference Interleukin-1 alp Raybiotec 126ELH-ILla ha h -1 Interleukin-8 Raybiotec h 126ELH-IL8-1 TNF-alpha Raybiotec h 126ELH-TNF a-1

[0300] These ELISA kits are intended for quantitative measurements of the cited markers, particularly in culture supernatants, using specific human antibodies. Samples and a range of standards are deposited in each well (96-well plate) in duplicate. The targeted marker present in a sample is bound by the antibody immobilized in the bottom of the well. The wells are washed and a biotinylated antibody is added. After washing, HRP-streptavidin is deposited in the wells. These are washed again, a TMB substrate solution is added to the wells and the color develops in proportion to the amount of bound marker. A revealing solution changes the color from blue to yellow, and its intensity is measured at 450nm using the Molecular Devices VMAX microplate reader. Absorbance values ​​are recorded and analyzed via SOFTmax PRO v4.7.1 software.The inflammatory response is interpreted as a sample / untreated ratio greater than or equal to 2.

[0301] Semi-quantitative fluorescence cytokine assay

[0302] In order to obtain a more complete profile of the anti-inflammatory effect induced by hydrogenated and highly branched dextrins, a panel of cytokines was assayed on slides by semi-quantitative assay. The cell culture supernatants collected after treatment of the epidermis are tested using the Human Cytokines Array G3 kit (RayBiotech).

[0303] On a glass slide containing the different specific antibodies, the supernatants are deposited at a rate of 100pL per well. A cocktail of secondary antibodies coupled to biotin is then added. Thanks to the addition of streptavidin, the signal intensities are detected by fluorescence. Each step is followed by several washes.

[0304] Results

[0305] MTT cell proliferation test

[0306] Cytotoxicity of the samples was tested using the epidermis model and is expressed as a percentage of the untreated control tissue (UTC).

[0307] [Tables3] Sample Description Viability %* SD%** Untreated control 100.0 Average DO obtained: 2.311 0.79 Positive control SLS 2% 0.9 0.35 Positive control SLS 0.5% (6 hours) 82.1 4.09 SLS 0.5% (6 hours) + Betamethasone Biogaran cream (0.05% Betamethasone) 77.1 2.88 SLS 0.5% (6 hours) + hyperbranched dextrins “Nutriose® HM 06” at 10% 79.5 3.96 SLS 0.5% (6 hours) + hyperbranched dextrins “Nutriose® HM 06” at 5% 78.2 3.62

[0308] * Average of the 3 replicates; **SD: standard deviation

[0309] A significant difference in cell viability is observed between the non-control treated and treated areas, demonstrating the impact of inflammatory treatment with SLS.

[0310] After 20 hours, cell viability in the presence of 0.5% SLS and Nutriose HM 06 hyperbranched dextrin is greater than 50%: thus Nutriose HM 06 hyperbranched dextrin is not an acute irritant for the epidermis. As expected, the same is true for the sample treated with 0.5% SLS and 0.05% betamethasone. Cell viability measured in the presence of 0.5% SLS and Nutriose® HM 06 hyperbranched dextrin is as good as in the presence of 0.5% SLS and betamethasone. This cell viability test having made it possible to establish that Nutriose HM 06 hyperbranched dextrin is not an acute irritant, tests on the expression of inflammation markers could be carried out in order to determine whether this dextrin can be described as either an irritant mild, in the case where there would be no reduction in expression of an inflammation marker, or anti-irritant, in the case where the expression of at least one major inflammation marker would be reduced.

[0311] Test on the inflammation marker IL-1a, IL-8 and TNF-a

[0312] [T ableaux4] Sample Description Sample Ratios / Untreated (quantity assayed) IL-1a IL-8 Untreated Control 1.0 (27 pg / mL) 1.0 (140 pg / mL) Positive Control 0.5% SLS (6 hours) 2.3 (61 pg / mL) 3.2 (453 pg / mL) 0.5% SLS (6 hours) + Betamethasone Biog aran cream (0.05% Betamethasone) 1.5 (41 pg / mL) 3.6 (511 pg / mL) 0.5% SLS (6 hours) + hyperbranched dextrins “Nutriose® HM 06” at 10% 1.6 (44 pg / mL) 3.5 (488 pg / mL) 0.5% SLS (6 hours) + hyperbranched dextrins “ Nutriose® HM 06” at 5% 1.7 (46 pg / mL) 3.6 (500 pg / mL)

[0313] The mean concentrations of the inflammation markers were calculated from two repetitions of n=3 epidermis in an ELISA test (except for IL-8, n=2). The ratios (concentration of the marker in the presence of the samples / concentration of the marker in the untreated control) were calculated for each formulation tested.

[0314] A ratio greater than or equal to 2 reflects overexpression of the inflammation marker while a ratio less than 2 indicates non-expression of the inflammation marker.

[0315] The hyperbranched dextrin "Nutriose® HM 06" according to the invention significantly reduces the expression of IL-1a (decrease of 25 and 28%). Betamethasone also significantly reduces the expression of IL-1a (decrease of 33%). Thus, no significant difference is observed between the compound according to the invention and betamethasone, a positive control testifying to the anti-inflammatory effect of the compound according to the invention.

[0316] None of the concentrations of hydrogenated and highly branched dextrins were able to decrease the expression of interleukin IL-8 after epidermal inflammation. Similarly, betamethasone cream had no effect on the IL-8 ratio. The expression of TNF-α was not significant enough to be detected according to the calibration curve of the ELISA kit.

[0317] Test on the 4 markers of inflammation IL-1a, IL-1 [3, RANTES and VEGF

[0318] Following the results obtained by ELIS A test on the inflammation marker IL1-a, The effect of the concentration of hyperbranched dextrin “Nutriose® HM 06” at 5% was evaluated after inflammation of the epidermis reconstructed with 5% SLS.

[0319] [Tables5] Sample Description Sample Ratios / Untreated IL-1a IL-1 [3 RANTE S VEGF Untreated Control 1.0 1.0 1.0 1.0 Positive Control SLS 0.5% (6 hours) 2.3 0.8 6.7 1.9 SLS 0.5% (6 hours) + hyperbranched dextrins “N utriose® HM 06” at 5% 1.3 0.4 5.7 1.6

[0320] *nd = not detectable, signal too weak

[0321] The ratios (intensity of the fluorescent signal of the marker in the presence of the samples / intensity of the fluorescent signal of the marker of the untreated control) were calculated for each treatment from n = 3 epidermal culture supernatants (except for the untreated control, n = 2).

[0322] A ratio >1.5 reflects overexpression of the inflammation marker.

[0323] A ratio < 0.65 reveals under-expression of the inflammation marker.

[0324] According to the supplier's criteria, the signals are usable when they are higher than the average of the background noise + 2SD. An overexpression or underexpression of 5 markers was observed with inflammation at SLS 0.5%. A decrease in the expression of these markers was also observed by the addition of the treatment based on hyperbranched dextrin "Nutriose® HM 06".

[0325] Thus, the hyperbranched dextrin “Nutriose® HM 06” reduces: - the expression of Il-la (vs SLS alone) and allows to go below the critical limit of 1.5 - the expression of II-1 [3 (vs SLS alone) and allows to go below 0.65 - the expression of 11-15 (compared to the untreated control) and allows to go below 0.65 - the expression of VEGF (compared to SLS alone) and allows us to approach the critical threshold of 1.5 - the expression of RANTES (vs SLS alone).

[0326] Nutriose HM 06 hyperbranched dextrin therefore reduces the expression of major markers of inflammation (IL-1 alpha and IL-1 beta), and can therefore be described as an anti-irritant. This dextrin has anti-inflammatory properties.

[0327] Example 2: In vitro determination of the effect of hyperbranched dextrins on membrane integrity on a 3D reconstructed human epidermis model

[0328] The objective of the study was to evaluate the membrane integrity of skin cells on a three-dimensional (3D) reconstructed human epidermis model, by measuring the amount of the enzyme lactate dehydrogenase (LDH) in the culture supernatant, by colorimetry. LDH is an enzyme that is released in the event of cell death. The absence of LDH secretion is a sign that the integrity of the epidermal cell membranes is preserved.

[0329] Protocol

[0330] Samples of 3D reconstructed human epidermis were immersed in an aqueous solution containing 0.5% by weight of sodium lauryl sulfate for 6 hours. Then the solution was removed, and the samples were immersed in different solutions for 20 hours: 1 sample in an aqueous solution of Nutriose® HM 06 at 5% by weight, another sample in an aqueous solution of bisabolol at 0.5% by weight, and another sample in an aqueous solution of betamethasone at 0.5% by weight. The amount of LDH secreted into the supernatant was then determined by colorimetry.

[0331] Results

[0332] Table 6] Sample description Membrane integrity (%) Untreated control 100 SLS 0.5% (6 hours) + bisabolol 0.5% (20 hours) 16.8 SLS 0.5% (6 hours) + hyperbranched dextrins “Nutriose® HM 06” at 5% (20 hours) 104.5 SLS 0.5% (6 hours) + betamethasone at 0.5% (20 hours) 110.7

[0333] Roquette Nutriose® HM 06 hyperbranched dextrin helps maintain the integrity of the cell membranes of reconstructed human epidermis, and does so as effectively as betamethasone.

[0334] Example 2: Clinical study on transepidermal water loss induced by shaving

[0335] The objective of the study is to determine the effect of a hyperbranched dextrin, sold under the reference Nutriose® HM 06 by Roquette, on transepidermal water loss (or TEWL according to the English term in use) induced by shaving of the skin of the face. through the topical application of said dextrin in the form of a lotion (aftershave), during a clinical study on volunteers.

[0336] Volunteers and products

[0337] This non-invasive, single-center study was conducted on sixty male volunteers aged between 30 and 55 years, with sensitive skin (based on their declaration), habitually using mechanical razors and applying aftershave. The inclusion criteria for the volunteers are presented in the table.

[0338] [Tables?] Criterion Sex Male Phototype III Age From 30 to 55 (divided into 3 homogeneous groups of average age) Sensitive skin Yes, based on voluntary declaration Type of regular razor Mechanical razor Application of regular aftershave

[0339] The volunteers were divided into three homogeneous groups of 20 volunteers, and each group received a batch of double-blade razor, “commercial reference” shaving cream, and an aftershave lotion according to the table below.

[0340] Compositions of aftershave creams

[0341] [Tables8] Volunteer group no. 1 2 3 Ingredient / Supplier INCI Placebo lotion Reference lotion Lotion according to the invention Aqua 96.8 96.3 91.8 Dragosantol® 100 Bisabolol 0 0.5 0 Nutriose® HMC06 Not available 0 0 5 Cosmedia® SP Sodium polyacryla te 0.2 0.2 0.2 Caprylis / Labrafac cc Caprylic capric triglycerides 2 2 2 Microcare® PHC Phenoxyethanol an d glycerin 1.00 1.00 1.00 Citric acid Qs pH 6 Qs pH 6 Qs pH 6

[0342] Material

[0343] The volunteers' faces are assessed by measuring transepidermal water loss (TEWL). This measurement allows an assessment of the skin's barrier function: the value of water loss is in fact inversely proportional to the skin's barrier function. The transepidermal water evaporation measurements, expressed in g / h / m2, were carried out on a Tewamètre TM300® from the manufacturer "Courage & Khazaka electronics", using the open room diffusion technique. Approximately twenty successive measurements are carried out on the surface of the face subjected to shaving, and an average value is retained.

[0344] Study procedure

[0345] Volunteers replaced their usual razor and shaving cream with the study razor and shaving cream three days before the start of the study. The study was then started by performing an assessment of the volunteers' faces in the laboratory after shaving and application of the aftershave lotion in the laboratory premises (measurement "day 0"). The measurement was repeated 10 minutes after the measurement "day 0".

[0346] Between Day 0 and Day 13, the volunteers performed their daily shave at home using a new razor for each shave, the study shaving cream and aftershave lotion. On Day 14, the volunteers returned to the laboratory for a facial assessment following a protocol identical to that of Day 0, i.e., an assessment after a shave followed by the application of the aftershave lotion in the laboratory, followed by a second measurement 10 minutes after the first.

[0347] Between day 14 and 27, the volunteers repeated the same protocol as between days 0 and 13. Then on day 28, they returned to the laboratory for a final facial assessment according to the same protocol as on day 0 and day 14: i.e. an assessment on day 28 after shaving and application of the aftershave lotion, followed by a second measurement 10 minutes after the first.

[0348] Results

[0349] [Tables9] TEWL Evaluation Group 1p laced Group 2 reference Group 3 invention Day 0 21.74 22.07 22.59 Day 0+10 minutes 19.51 16.88 18.83 Day 14 21.38 22.58 22.40 Day 14 + minutes 19.65 18.98 19.39 Day 28 19.98 20.77 24.19 Day 28 + 10 minutes 18.99 18.02 19.58

[0350] [TableauxlO] Variation (Day x + 10 minutes) - Day X Group 1p laced Group 2 reference Group 3 invention Day 0 -2.24 -5.19 -3.77 Day 14 -1.73 -3.60 -3.01 Day 28 -0.99 -2.75 -4.62

[0351] The study thus showed that the application of an aftershave lotion comprising the hyperbranched and hydrogenated dextrin according to the invention, Nutriose HMC 6, made it possible to reduce intracellular water loss compared to the placebo lotion from day 0 and on days 14 and 28. This also made it possible to reduce water loss on the 14th day in a manner equivalent to the reference product, and to reduce water loss on the 28th day in a manner greater than the reference product.

[0352] Example 3: Clinical study on transepidermal water loss (TEWL) and redness induced by sodium lauryl sulfate

[0353] The objective of the study is to determine the effect of a hyperbranched dextrin, sold under the reference Nutriose® HM 06 by Roquette, on the redness created by irritation of the skin of the inner forearm by a 10% SLS patch test, during a clinical test on volunteers.

[0354] Volunteers and products

[0355] The volunteers were the same as for the clinical study of Example 2 (shaving study), divided into the same groups, with the same products (Table 6 of Example 2).

[0356] Materials

[0357] Skin color was assessed by colorimetry using a chromameter "spectrocolorimeter CM2600D TM" from the manufacturer Minolta. Color measurements were made according to the following parameters: standard field of view of 10°, illumination D65 corresponding to daylight, measurement on square areas of 8 mm side, color space used L*a*b*, SCI method (specular included) to free oneself from surface conditions.

[0358]

[0359]

[0360]

[0361] The vertical dimension L* represents brightness (or luminance) with values ​​ranging from 0 (black) to 100 (white). The parameter a* determines a range of 600 levels on the red axis (+299 positive values) through gray (value of 0) to green (-300 negative values). The parameter b* determines a range of 600 levels on the yellow axis (+299 positive values) through gray (value of 0) to blue (-300 negative values). For this study, the parameter a*, representing skin redness, was determined. Study protocol At the start of the study (day 0), skin color and TEWL measurements were taken on demarcated areas on both forearms of the volunteers. Then, 10% SLS patches were placed on the two demarcated areas on each volunteer's forearms. The volunteers kept the patches on for 20 hours, and removed them 4 hours before the day 1 measurement, so that on day 1, color and TEWL measurements were taken on both forearms of all volunteers. Immediately after the day 1 measurement, aftershave lotion was applied to the SLS patch-treated area on the right forearm, and then color and TEWL were measured 5, 10, and 30 minutes after this application. The left forearm received no treatment. From day 1 to day 6, volunteers applied aftershave lotion daily in the evening to the SLS-treated area of ​​the right forearm. The left forearm received no treatment. On days 2, 3, 4, and 7, the color and TEWL of the aftershave lotion-treated area and the control area were measured.

[0362]

[0363] Results Placebo group Reference group Invention group Parameter a* Treated Untreated Treated Untreated Treated Untreated Day 0 4.56 5.05 4.46 4.88 4.29 4.81 Day 1 6.17 6.12 6.92 6.45 6.41 6.29 Day 1+5 min 6.11 6.05 6.67 6.19 5.74 6.00 Day 1 + 10 min 5.89 6.07 6.80 6.09 5.49 6.02 Day 1+30 min 6.01 5.59 6.20 5.80 5.28 5.88 Day 2 6.51 6.68 6.75 6.90 6.43 7.13 Day 3 6.54 7.05 6.95 7.30 6.66 7.37 Day 4 6.55 6.80 6.51 6.38 6.43 6.81 Day 7 5.97 6.09 5.96 5.87 5.67 6.25

[0364] To compare the changes in redness between the different groups, the variations in redness between the different measurement times were calculated, for example for a treated area of ​​skin:

[0365] [Math.l]

[0366] Treated((Day x) - Day 1) ~ (a* of the treated area on day x) - (a* of the treated area on day 1). for the three groups. Variation of parameter a* Placement group Reference group Invention group ATreated((Day 1 + 5 min) - Day 1) - AUntreated((Day 1 + 5 min) - Day 1) -0.02 0.02 -0.38 ATreated((Day 1 + 10 min) - Day 1) - AUntreated((Day 1 + 10 min) - Day 1) -0.23 0.24 -0.66 ATreated((Day 1 + 30 min) - Day 1) - AUntreated((Day 1 + 30 min) - Day 1) 0.38 -0.06 -0.73 ATreated((Day 2) - Day 1) - AUntreated((Day 2) - Day 1) -0.22 -0.61 -0.82 ATreated((Day 3) - Day 1) - AUntreated ((Day 3) - Day 1) -0.55 -0.81 -0.84 ATreated ((Day 4) - Day 1) - AUntreated ((Day 4) - Day 1) -0.30 -0.33 -0.50 ATreated ((Day 7) - Day 1) - AUntreated ((Day 7) - Day 1) -0.17 -0.37 -0.70 The table represents the differences in redness variations over time between treated and untreated skin areas.

[0367]

[0368] Nutriose® HM 06 hyperbranched dextrin significantly reduced redness caused by SLS after 10 minutes compared to the placebo and reference groups, and this reduction was maintained for up to 7 days. The reduction in skin redness by applying Nutriose HM 06 hyperbranched dextrin showed that this dextrin reduced skin inflammation caused by the 10% SLS patch. In addition, this reduction in inflammation was faster than for the reference group, and therefore faster than for the known anti-inflammatory Bisabolol.

[0369] Parameter a* Placebo group Reference group Invention group Day 0 8.88 9.35 9.42 Day 1 19.12 23.95 24.27 Day 1+30 min 18.78 23.17 19.21 Day 2 20.28 23.44 23.17 Day 3 19.37 20.74 21.22 Day 4 15.68 16.38 16.82 Day 7 15.73 14.55 14.24 The table represents transepidermal water losses on the treated areas of the forearm

[0370]

[0371]

[0372]

[0373]

[0374]

[0375]

[0376] Parameter a* Placebo group Reference group Invention group (Day 1 + 30 min) - day 1 -0.34 -0.775 -5.06 Day 2 - day 1 1.16 -0.505 -1.095 Day 3 - day 1 0.245 -3.205 -3.045 Day 4 - day 1 -3.436 -7.565 -7.445 Day 7 - day 1 -3.39 -9.4 -10.025 Table 14 represents the variations in transepidermal water losses on the treated areas of the forearm compared to day 1. Nutriose® HM 06 hyperbranched dextrin significantly reduced transepidermal water loss from 30 minutes after application, then gradually increased over the treatment period from 2 to 7 days, reaching a water loss reduction value compared to the placebo group that was approximately 6.6 units greater (a difference of approximately 195%). This hyperbranched dextrin therefore helped maintain skin hydration by maintaining the skin's barrier function. Example 4: Cosmetic product formulations comprising a hydrogenated and highly branched dextrin according to the subject matter of the application “Skin lover” cream (SC-079-005) [Tables 15] INCI Phase Trade name Supplier Al Aqua Demineralized water 59.93 Not available Nutriose HM 06 Roquette 5.00 A2 Xanthan gum Keltrol CG CP Kelco 0.30 Microcrystalline cellulose, cellulose gum Tabulose SC 611 Itacel 1.00 A3 Cyclodextrin, sorbitol, polyglycer yl-3-diisostearate Beauté by Roquette DS 146 Roquette 5.00 B Diheptyl succinate, capryloyl gly cerin / sebacic acid copolymer Lexfeel N350 Inolex 20.00 C Zea mays starch Beauté by Roquette ST 005 Roquette 5.00 D Gluconic acid, caprylyl / capryl glucoside, cymbopogon Beauté by Roquette LS 007 Roquette 1.00 E Aqua Demineralized water 2.00 Potassium sorbate Microcare KS Thor 0.40 F Fragrance Delicious apple IPO Laboratoires LRFlavours & Fragrance s industries S .pA 0.30 Aqua and Cl 42090 FDC blue one (aqueous solution 2%) Sensient 0.07

[0377] Preparation protocol: At 45°C, Nutriose® HM 06 was added to the water and mixed with a deflocculator at 500 rpm until a clear solution was obtained. The ingredients of phase A2 were then mixed together in the water while stirring at 500-1000 rpm. Phase A3 was then added to phase A1+A2, and mixed at 1500 rpm for 10 minutes. Separately, phase B was prepared by heating it to 45°C, then the liquid phase B was emulsified in phase A1+A2+A3 at 45°C while stirring at 2000-3000 rpm for 15 minutes. It was then cooled to room temperature, and phases C and D were added. Finally, E and F, previously dissolved in a little water, were added. A blue-colored emulsion was thus obtained, with a Brookfield viscosity of 4500-5500 mPa.s (SP3 mobile, 20 rpm, 20°C).

[0378] After-sun cream

[0379] [Tables 16] Phase INCI Nom commercial Fournisseur A Aqua Demineralized water / To 100 Sorbitol Beauté by Roquette® PO 071 Roquette 5 Non disponible Nutriose HM 06 Roquette 5 Xanthan gum Xanthan gum FNCSP-P C JBL 0.3 Polyglyceryl-10 Laurate Emulpharma Eco 10 Res Pharma 3 B Hydrogenated Argania Spi no s a Kernel Oil Nat Organic Argan Wax Naturochim 2 Butyrospermum Parkii (S hea) Butter Beurre de karité Aromazone 3 Jojoba Esters and Heliant hus Annuus (Sunflower) S eed Wax (and) Acacia De currens Flower Wax (and) Polyglycerin-3 Acticire MB Gattefossé 5 Argania Spinosa (argan) Kernel Oil Huile d'argan vierge déso dorisée Cooper 12 Tocopherols (mixed), heli anthus annuus seed oil Vitamine E Aromazone 0.2 C Aluminium starch octenyl succinate Beauté by Roquette® ST 012 Roquette 3 D Aqua Demineralized water / 5 Potassium sorbate Potassium sorbate Cooper 0.4 Sodium benzoate Sodium benzoate Cooper 0.4

[0380] Preparation protocol: Phase A and phase B were prepared at 70°C in two separate beakers. Phase B was then emulsified in phase A under high shear stirring for 10 minutes. It was then cooled to 20°C + / -2°C. Phase C was then added under stirring, followed by phase D. The pH was finally adjusted to 6. A white cream was obtained, with a Brookfield viscosity of 3500 mPa.s + / - 700 (spindle no. 4 at 20 rpm).

[0381] Aftershave gel

[0382] [Tables 17] INCI Phase Trade name Supplier A Aqua Demineralized water / To 100 Isosorbide Beauté by Roquette® P 0 500 Roquette 5 Stach acetate, hydroxyethyl cellulose and xanthan gum Beauté by Roquette® DS 112 Roquette 3 Not available Nutriose HM 06 Roquette 5 B1 Aqua Demineralized water / 5 Potassium sorbate Potassium sorbate Cooper 0.4 B2 Gluconic acid, caprylyl / cap ryl glucoside, cymbobogon citratus leaf oil Beauté by Roquette® LS 007 Roquette 1 C Sodium hydroxide 18% Sodium hydroxide 18% / qs pH 5.5-6

[0383] Preparation protocol: isosorbide and Nutriose HMC 06 were first mixed in the quantity of water required for phase A, then Beauté by Roquette DS 112 starch was dispersed in it at 80°C for 30 to 40 minutes. Phases B1 and B2 were then added successively, and the pH was adjusted to 6. A translucent gel was obtained, with a Brookfield viscosity of 3500 mPa.s + / -700 (spindle no. 4 at 20 rpm).

[0384] Soothing oil-in-water emulsion

[0385] [Tablesl8] Phase INCI Nom commercial Fournisseur Al Aqua Demineralized water / 61.93 Non disponible Nutriose HM 06 Roquette 5.00 A2 Xanthan gum Keltrol CG CP Kelco 0.30 Microcrystallin cellulose, c ellulose gum Tabulose Roquette 1.00 A3 Cyclodextrin, Sorbitol, Pol yglyceryl-3 diisostearate Beauté by Roquette® D S 146 Roquette 5.00 B Diheptyl Succinate, Capryl oyl Glycerin / Sebacic Acid Copolymer Lexfeel N350 Inolex 20.00 C Zea Mays Starch Beauté by Roquette® S T 005 Roquette 5.00 D Gluconic acid, caprylyl / Ca pryl glucoside, cymbopogo n citratus leaf oil Beauté by Roquette® L S 007 Roquette 1.00 E Potassium sorbate Microcare KS Thor 0.40 F Perfum Delicious apple IPO LR 0.30 Colour E 133 FDC blue 1 (2% sol. aq •) 0.07

[0386] Preparation protocol: Nutriose HMC 06 was added to half the volume of water required for the formulation at 45°C with stirring using a deflocculator at 500 rpm until a clear solution was obtained. Separately, the ingredients of phase A2 were mixed in half the volume of water required for the formulation with stirring at 500-1000 rpm. Phase A1 and phase A2 were then mixed, and phase A3 was added with stirring at 1500 rpm for 10 minutes. Separately, phase B was prepared by heating it to 45°C. Then, phase B was emulsified in phase A1+A2+A3 with vigorous stirring at 2000-3000 rpm for 15 minutes at 45°C. The mixture was cooled to 20°C + / -2°C, then phases C, D, E and F were added successively while stirring at 500 rpm, and the pH was adjusted to 5.3 + / -0.2. This gave a blue-colored emulsion with a Brookfield viscosity of 4500-5500 rnPa.s (spindle no. 3 at 20 rpm).

[0387] Soothing and restorative hand cream

[0388] [Tablesl9] INCI Phase Trade name Supplier A Aqua Water - 60.3 Not available Nutriose HM 06 Roquette 5 B Starch Acetate, Starch sodium octenylsuccinate, Guar gum, Tara gum, Xanthan gum Beauté by Roquette DS 421 Roquette 3 C Prunusamygdalusdulcis oil Sweet almond oil Cooper 30 Fragrance Nola FreshJuice LRFlavours & Fragrances 0.2 Benzyl alcohol Microcare alcohol BNA Thor 0.5 D Gluconic acid, caprylyl / Ca pryl glucoside, cymbopogon citratus leaf oil Beauté by Roquette LS 007 Roquette 1

[0389] Preparation protocol: Nutriose HMC 06 was added to the volume of water required for the formulation at 45°C with stirring using a deflocculator at 500 rpm until a clear solution was obtained, then cooled to 20°C + / -2°C. Beauté by Roquette DS 421 was then dispersed in phase A with stirring using a deflocculator at 1000 rpm for approximately 10 minutes so that this ingredient was hydrated, which which was visually observed by its opalescence. Separately, phase C was prepared. At room temperature (20°C + / - 2°C), phase C was added to phase A + B slowly and with stirring using a deflocculator at 2000-3000 rpm, then stirring was maintained for 10 minutes. Finally, phase D was added with stirring at 1000-2000 rpm, then adjusted to pH 4.5-4.7. A yellow cream was obtained, with a Brookfield viscosity of 8800 mPa.s (spindle 3 at 20 rpm).

[0390] Soothing Cleansing Cream (TO-027-001)

[0391] [Tables20] Phase INCI Trade name Supplier Al Aqua Demineralized Water - 28.3 Not available Nutriose HM 06 Roquette 5 Phenoxyethanol (and) Chlorphenesin Microcare PHC Thor 1 D Sodium Lauryl ether Sulfate Texapon NS O UP BASF 7 Coco Glucoside Pureact Gluco C Innospec 5 Disodium Laureth Sulfosuccinate Rewopol SB FA 30 B Evonik 5 Cocamidopropyl Betaine Dehyton PK45 BASF 7

[0392] Soothing Hair Conditioning Gel (HC-040-001)

[0393] [Tables21] INCI Phase Trade name Supplier Al Aqua Demineralized water / 81 Maltitol Beauté by Roquette ® PO 455 Roquette 5 Not available Nutriose HM 06 Roquette 5 A2 Starch acetate, Hydroxyethyl-cellul ose, Xanthan gum Beauté by Roquette ® DS 112 Roquette 5 A3 Cetrimonium Chloride Microcare Quat CTC 30 Thor 3 B Phenoxyethanol, Chlorphenesin, G lycerin Microcare PHC Thor 1

[0394] Soothing Conditioning Cream for Hair (HC-040-002)

[0395] [Tables22] Phase INCI Trade name Supplier Al Aqua Demineralized water / Maltitol Beauté by Roquette ® PO 455 Roquette Not available Nutriose HM 06 Roquette A2 Starch acetate, Hydroxyethyl-cellulose, Xanthan gum Beauté by Roquette ® DS 112 Roquette A3 Cetrimonium Chloride Microcare Quat CTC 30 Thor B Caprylic capric triglycerides Caprylis Aroma Zone C Phenoxyethanol, Chlorphenesin, G lycerin Microcare PHC Thor

Claims

Claims

1. Hyperbranched dextrins comprising: - at most 70% of 1-4 glucosidic bonds, - at least 5% of 1-6 glucosidic bonds, relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, for their topical use for the prevention or treatment of at least one symptom of skin inflammation chosen from redness, heat, swelling and pain.

2. Hyperbranched dextrins for their use according to claim 1, characterized in that the dextrins are hydrogenated hyperbranched dextrins.

3. Hyperbranched dextrins for their use according to claim 1 or 2, characterized in that the symptom is located at the level of the keratinized multi-stratified squamous epithelium.

4. Hyperbranched dextrins for use according to any one of claims 1 to 3 for the prevention or treatment of skin inflammation.

5. Hyperbranched dextrins for their use according to claim 4, characterized in that the skin inflammation is induced by skin irritation, skin corrosion, skin inflammation of endogenous origin, or a combination of these causes.

6. Hyperbranched dextrins for their use according to any one of the preceding claims, characterized in that the at least one symptom or skin irritation or skin corrosion or skin inflammation is induced by at least one of the conditions chosen from infectious agents, chemical products, ingredients contained in cosmetic, dermatological, pharmaceutical, veterinary, detergent or domestic compositions, mechanical aggressions, environmental factors, thermal aggressions, foods and drinks.

7. Hyperbranched dextrins for their use according to any one of the preceding claims, characterized in that the skin irritations are chosen from cumulative irritant contact dermatitis, acute irritant contact dermatitis, and phototoxic dermatitis.

8. Hyperbranched dextrins for their use according to claim 4, according to which the skin inflammation is induced by a dermatological pathology involving an inflammatory process.

9. Hyperbranched dextrins for their use according to claim 9, characterized in that the pathology is chosen from erythema, psoriasis, cutaneous atopy, atopic dermatitis, allergic reactions of immediate hypersensitivity type, allergic reactions of delayed hypersensitivity type, inflammatory hyperpigmentations, immune dermatoses, actinic elastosis, alopecia areata, vitiligo, systemic lupus erythematosus, pemphigus vulgaris, dystrophic epidermolysis bulbosa and canities of autoimmune origin, erythema.

10. Hyperbranched dextrins comprising: - at most 70% of 1-4 glucosidic bonds, - at least 5% of 1-6 glucosidic bonds, relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, for preventing or reducing or eliminating the irritant effect of ingredients contained in cosmetic or dermatological, medicinal, veterinary, detergent or domestic compositions.

11. Use of hyperbranched dextrins according to claim 10, characterized in that the ingredients are chosen from surfactants, perfumes, solvents, preservatives, acids, bases, detergents.

12. Hyperbranched dextrins according to any one of claims 1 to 9 or use according to claims 10 or 11, characterized in that the hyperbranched dextrins have: - from 42 to 50% of 1-4 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, - from 5% to 40% of 1-6 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-3 glucosidic bonds relative to the sum of the 1-2, 1-3, 1-4 and 1-6 bonds, - from 1 to 20% of 1-2 glucosidic bonds relative to the sum of the 1-2, 1-3 bonds, 1-4 and 1-6.

Images